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Resumo 
O vírus influenza A é o agente causador de epidemias e pandemias de gripe, com forte 
impacto na população. O estudo do ciclo de replicação do vírus, e das vias celulares que 
utiliza, constitui uma resposta às limitações associadas à vacinação ou prescrição de 
drogas antivirais.  
O genoma deste vírus é constituído por 8 segmentos (vRNPs), que são replicados no 
núcleo da célula hospedeira e exportados para o citoplasma onde se dá a montagem do 
virião e saída para o espaço extracelular. Para a montagem, todos os componentes 
necessitam de chegar a locais específicos da célula. O recycling endosome é um 
compartimento usado pelo vírus para o transporte de vRNPs para estes locais na 
membrana plasmática. No entanto, apenas a proteína celular Rab11 foi identificada como 
reguladora deste processo. Para além das Rab, o transporte vesicular também é regulado 
pela família ADP-ribosylation factors (ARF). Um rastreio de 26 membros da família de 
proteínas ARF foi realizado em células infectadas com o vírus influenza A e revelou um 
candidato, ARF-like 15 (ARL15), objecto de estudo desta tese.  
Os resultados obtidos demonstram que a ARL15 influencia positivamente a infecção, visto 
que a sua depleção reduziu em dez vezes os títulos virais, efeito revertido após expressão 
exógena da proteína. Adicionalmente, a localização intracelular da ARL15 mostrou-se 
sensível à infecção com influenza A, com translocação da proteína do cis-Golgi para um 
compartimento não-identificado nas fases iniciais da infecção. Ensaios de silenciamento 
resultaram na acumulação citoplasmática de vesiculas com vRNP, sugerindo que a 
proteína ARL15 tem uma função no transporte de vRNPs para os locais de montagem do 
viriao. Mais ainda, o nosso trabalho sugere que a ARL15 pode contribuir para a 
inactivação da Rab11 visto afectar negativamente a ligação dos vRNP à Rab. A 
inactivação da Rab11 é um novo passo necessário para a formação do complexo 
genómico que contém os 8 segmentos. A formação deste complexo está na origem de 
estirpes que causam pandemias. A identificação de novos mecanismos entre o 
hospedeiro e o vírus no que toca à montagem do virião é importante para a 
implementação de estratégias antivirais. 
 
Palavras-chave: Vírus influenza A, família ARF, proteínas ARL, trafego de vRNPs, 
montagem do virião.  
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Abstract 
Influenza A virus (IAV) is the infectious agent that causes epidemic and pandemic events 
of flu, which have high impact in the human population. The study of the viral lifecycle, and 
the cellular pathways that it highjacks, presents an alternative avenue for treatment of IAV 
infection, as current vaccines and antiviral treatments present many drawbacks.  
The virus has an eight-part segmented RNA genome in the form of ribonucleoproteins 
(vRNPs) which are replicated in the nucleus of the host cell but must be exported to the 
cytoplasm for viral assembly, budding and release. Assembly comprises convergence of 
all virion components to specific sites in the cell. vRNPs use the recycling endosome for 
transport to the assembly sites at the plasma membrane. Only one host protein, Rab11, 
has been defined to participate in this process. In addition to Rab proteins, vesicular 
transport is also regulated by the family of ADP-ribosylation factors (ARF). A preliminary 
screen involving 26 members of the ARF-family in IAV infected cells resulted in the 
identification of a promising candidate protein, ARL15, which for this reason is the object of 
study in this thesis.  
We demonstrate that ARL15 positively impacts IAV infection as its depletion leads to a 10 
fold reduction in virus production, which was reverted by overexpressing ARL15. 
Furthermore, ARL15’s intracellular localization was sensitive to infection, by translocating 
from the cis-Golgi to an unidentified compartment, at the early stages of infection. The 
depletion of ARL15 resulted in the accumulation of vRNP-carrying vesicles in the 
cytoplasm, suggesting that ARL15 plays a role in transporting vRNPs to sites of virion 
assembly. Additionally, we present indirect evidence that ARL15 might contribute to a step 
in infection subsequent to vRNP ligation to Rab11 vesicles and we propose that it might 
promote Rab11 inactivation. This is a novel step in infection of IAV involved in the 
formation of the 8-segment genome core. Assembly of the genome core is the basis of 
reassortment that leads to the emergence of pandemic strains and therefore, unraveling 
key host-pathogen mechanisms underlying viral assembly will certainly contribute to 
implement novel antiviral strategies.  
 
Keywords: influenza A virus, IAV, ADP-ribosylation factor-like, ARL, ARF-family, vRNP 
trafficking, IAV assembly. 
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CHAPTER 1 | Introduction 
 
1.1. Influenza – Impact and Disease 
Influenza viruses are the infectious agents responsible for a contagious acute 
respiratory disease, commonly referred to as flu1, an important disease in humans. It 
causes yearly epidemics with associated high mortality and economic burden, and 
occasional pandemics of devastating consequences. For these reasons, circulating 
influenza viruses in humans are continuously surveilled, as the basis for vaccine 
production to mitigate dramatic outcomes of the infection. There are three types of 
influenza viruses: A, B and C, all associated with human disease and provoking different 
levels of severity2. 
Influenza A viruses (IAV), the most relevant of the three types to human health, are 
found in various animals including humans, pigs, bats, horses, and wild birds, the latter 
being the primary reservoir for most subtypes of influenza A viruses3. The vast diversity 
among IAV has led to the establishment of categories based on the viral antigens, i. e. the 
two main proteins at the surface of the virus: hemagglutinin (H or HA) and neuraminidase 
(N or NA). There are 18 different hemagglutinin and 11 neuraminidase subtypes4,5 (H1 to 
H18 and N1 to N11 respectively that are shown in table 1.1).  
This diversity, in part, originates from the viral optimization to the biology of each 
host it infects to increase its fitness. The viral fine-tuning to each biological system results 
in the restriction of viral growth to species sharing similar processes. However, on rare 
occasions, IA viruses are able to jump the species barrier, infecting other hosts5. These 
events have had serious impact in human health, provoking disease of variable outcomes. 
Table 1.2 summarizes IAV outbreaks of different origins that occurred in humans during 
recent history with variable severity. These outbreaks include sporadic incursions of 
viruses, such as the avian strains H5N16 and H7N97, that resulted in high mortality rates in 
infected people but were unable to become established in the human population. These 
infections did not spread, but had a global effect in creating awareness to potential 
pandemics. The table also includes viruses that provoked generalized disease, such as 
the well-known Spanish Flu that killed over 40 million people worldwide8. In this particular 
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case, the virus was able to successfully establish in the human population and to be 
perpetuated, causing annual episodes of influenza infections that are normally known as 
epidemic or seasonal influenza.  
Table 1.1. Diversity in subtypes of viral surface proteins HA and NA, with host distribution. Adapted from
4 
Hemagglutinin Neuraminidase 
  Subtype People Poultry Pigs Bats/ other Subtype People Poultry Pigs Bats/ other 
H1 ● ● ● 
 
N1 ● ● ● 
 
H2 ● ● ● 
 
N2 ● ● ● 
 
H3 ● ● ● other animals N3 
 
● 
  
H4 
 
● ● other animals N4 
 
● 
  
H5 ● ● ● 
 
N5 
 
● 
  
H6 ● ● 
  
N6 ● ● 
  
H7 ● ● 
 
other animals N7 ● ● 
 
other animals 
H8 
 
● 
  
N8 ● ● 
 
other animals 
H9 ● ● ● 
 
N9 ● ● 
  
H10 ● ● 
  
N10 
   
bats 
H11 
 
● 
  
N11 
   
bats 
H12 
 
● 
       
H13 
 
● 
       
H14 
 
● 
       
H15 
 
● 
       
H16 
 
● 
       
H17 
   
bats 
     
H18 
   
bats 
      
 
The establishment in a new host requires adaptation to a different biological 
environment3. To accomplish these adaptations, the virus uses many strategies, taking 
advantage of the nature of its genome, which is RNA of negative polarity, and composed 
of eight different segments that work as independent entities2. The virus has high mutation 
rates, on account of the error prone RNA polymerase that it encodes39. This results in 
constant mutations that reshape viral antigens (antigenic drift) and allow continued 
infections in the same host. Second, in addition to mutagenesis, the segmented nature of 
the virus allows genome mixing upon co-infection of the same cell, a process called 
reassortment. Reassortment greatly augments viral diversity and evolution and may 
produce antigenic shifts (substitution) in the combination of HA-NA subtypes present in the 
surface of the virion10. Such complex events are for example behind the pandemics of 
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1957, 1968 and 2009 (Table 1.2, below). In both cases, host species jump or viral 
reassortment, strains unknown to the immune system may emerge with unpredictable 
consequences to human health.  
 
Table 1.2. Human IAV outbreaks in recent history.  
Year Subtype Name Event Origin Statistics Ref 
1889-92 H2N2(?) Russian Flu Pandemic (?) 
1 million deaths 
worldwide. 
8
  
1918-57 H1N1 Spanish Flu Pandemic Avian 
40 to 50 million deaths 
worldwide. 
8
 
1957-68 H2N2 Asian Flu Pandemic 
Avian, 
human 
1 to 2 million deaths 
worldwide. 
8
 
1968-69 H3N2 
Hong Kong  
Flu 
Pandemic 
Avian, 
human 
1-3 million infected, 700 
000 deaths worldwide. 
8
 
1969-
Present 
H3N2 - Seasonal - 
40 000 deaths per year 
(overall seasonal data). 
11,12
 
1977-
2009 
H1N1 
Russian Flu 
epidemic 
Epidemic then 
Seasonal 
Reintroduced 
strain 
Epidemic caused 70 000 
deaths in the USA. 
8
 
1999 H9N2 - New strain Avian 
Illness in 2 children in 
Hong Kong. Zero deaths. 
13
 
2003 H7N7 - New strain Avian 
83 confirmed cases in 
Netherlands, zero deaths. 
14
 
2003-
Present 
H5N1 - 
New strain with 
pandemic potential 
Avian 
700 infections, 400 
deaths.  
6
 
2004 H7N3 - New strain  Avian 
2 infected zero deaths in 
Canada. 
15
 
2009-10 H1N1 
Swine/ 
Mexican Flu 
Pandemic 
Avian, 
human, 
swine 
Over 18 000 deaths 
worldwide. 
16
 
2010-
Present 
H1N1 - Seasonal - 
40 000 deaths per year 
(overall seasonal data). 
11,12
 
2013-
Present 
H7N9 - 
New strain with 
pandemic potential 
Avian 
571 laboratory-confirmed 
cases, 212 deaths in 
China.  
7
 
 
Epidemic strains currently circulating in humans include the H1N1 and H3N212. 
These strains have become established in humans after the pandemic events of 2009 and 
1968, respectively. Mutations lead to the selection of strains with modified epitopes of HA 
or NA10. Immune defenses developed against the viral proteins HA and NA were no longer 
able to recognize the new antigens, and thus would not protect the infected individual17. 
According to the World Health Organization and the European Center for Disease 
Prevention and Control (ECDC), every year approximately 100 million people are affected 
by IAV in Europe, Japan and the USA, and nearly 40 thousand people die prematurely in 
the European Union alone11. The infectious period usually lasts a week, with patients 
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presenting sore throats, body aches and fatigue. Even though most individuals recover 
without requiring medical treatment, people suffering from diabetes, asthma, heart 
disease, cancer, pregnant women, children, the elderly and immunocompromised 
individuals are considered risk groups. In these cases, infection can lead to severe 
medical complications, such as pneumonia, and even result in death1.  
In order to mitigate the effects of influenza infection, a yearly vaccination program 
has been implemented worldwide. Surveillance provides data on circulating strains and 
predicts the ones that are most likely to become prevalent in the following year18. Vaccines 
are updated once the reactivity of produced antibodies to circulating strains diminishes17. 
This expensive updating system requires constant investigation and surveillance as it is 
based on predictive methods that are not devoid of error. Last year, vaccines designed for 
the northern hemisphere failed to include a H3N2 strain that became prevalent during the 
flu season, reaching 70% of H3N2 cases of infection19. Figure 1.1a illustrates the switch in 
the prevalent subtype from H1N1 to H3N2 by analyzing circulating viruses in humans over 
the years of 2013-2015. During this period, the vaccine composition was not updated, with 
the trivalent vaccine including the following strains: H1N1 (A/California/7/2009 pandemic-
like virus), H3N2 (A/Texas/50/2012-like virus) and influenza B (B/Massachusets/2/2012-
like virus)20. The analysis of patient’s samples by the Center for Disease Control (CDC, 
USA) concluded that individuals were producing antibodies that reacted against an 
antigenically and genetically distinct strain of influenza A H3N2 to that in circulation. This 
new variant had suffered an antigenic drift escaping the immune response developed to 
the H3N2 strain included in the vaccine. Figure 1.1b highlights the reshaping of the viral 
protein HA, the most abundant of the viral proteins at the surface of the virus. The 
prevalence of H3 subtype, over that of H1, was a novel epidemiological mark and greatly 
increased the effect of H3 inefficient vaccines. This vaccine was updated for administration 
to the southern hemisphere to include the strain H3N2 A/Switzerland/9715293/2013 which 
showed to be effective in preventing viral infection. 
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A 
 
Figure 1.1. Emerging new H3N2 strain during 
2014-15 winter season. a) Number and subtypes 
of influenza specimens circulating worldwide during 
winter season 2013-14 and 2014-15
21
. b) Changes 
in epitopes of HA between the H3N2 
A/Texas/50/2012 vaccine strain and most viruses 
isolated during the 2014–2015 Northern 
Hemisphere influenza season. Altered residues: 
L3I, T128A, A138S, R142G, N144S, N145S, F159Y 
or F159S, K160T, N225D, Q311H
22
. 
 
 
     B 
 
 
                          
 
 
 
 
 
 
 
 
 
In 2015, the CDC issued a statement informing the general population of the 
inefficacy of the vaccine due to the widespread dissemination of the mutated H3N2 
strain23. Medical staff were instructed to pay special attention to patients presenting flu-like 
symptoms, and to directly prescribe antiviral medication. Antivirals currently available are 
inhibitors of viral protein neuraminidase function, thus preventing viral release. The drugs 
would reduce symptoms, shorten the length of illness, keep patients out of hospitals and 
prevent further spread of the virus. Supported by the current situation with antibiotics, the 
widespread prescription of antivirals to symptomatic patients generated controversy, 
based on the possibility of emergence of more aggressive and resistant strains in the 
population24. In accordance, drugs administered in the past that targeted viral entry are no 
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longer effective in combating circulating strains24. The low numbers of effective antivirals to 
overcome influenza infections has led to an increase in research to identify novel 
therapeutical strategies.  
Influenza B viruses also contribute to the burden of seasonal epidemics. However, 
contrary to IAV, antigenic differences in influenza B are limited as illustrated by the two 
lineages that circulate since the 1980s: Victoria and Yamagata25. Mutagenesis rate in 
antigenic proteins is lower in influenza B, and thus antigenic drift was suggested to have a 
much less significant role in flu epidemics3. The host range of influenza B is restricted to 
humans and seals26. Despite the limited number of susceptible hosts, it has been shown 
that influenza B is capable of undergoing genome mixing by reassortment, but the 
significance of these phenomena in epidemics is yet to be understood27.  Although 
significant, the number of cases of influenza B in humans is inferior to those provoked by 
influenza A (figure 1.1a), but still justifies its inclusion in vaccines12.  The symptoms of 
influenza B are less severe than those attributed to IAV and the lack of an animal reservoir 
and differences with IAV prevents severe outbreaks and pandemics in humans. 
Consequently, influenza B constitutes a smaller problem for human health27. 
Influenza C viruses cause only mild infections in humans and pigs, and are 
associated with infrequent cases of localized outbreaks28. The impact of these infections is 
very low, and this type is not considered during vaccine design3. 
Overall, IAV is a major human pathogen with severe impact in human population. 
In spite of tight surveillance, yearly updated vaccination and extensive antiviral drug 
development incentives, the virus continues to provoke epidemics and occasional 
pandemics with severe outcomes. Therefore, novel strategies to target IAV infection are 
required, whose identification greatly depends on the thorough knowledge of IAV lifecycle 
and the characteristics of the virion.   
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1.2. Influenza A – Virion 
 The influenza A virus represented in figure 1.2a belongs to the Orthomyxoviridae 
family. It  has a viral envelope derived from the host lipid bilayer containing the surface 
proteins: HA, NA and matrix protein 2 (M2)32,33. The inner core of the viral particle contains 
matrix protein 1 (M1), nuclear export protein (NEP, also named non-structural protein 2, 
NS2) and the viral genome. The virus genome is divided into eight segments of negative-
single-stranded RNA (vRNA) coated by multiple subunits of nucleoprotein (NP), placed 
every twenty-four nucleotides, and attached to the heterotrimeric viral RNA-dependent 
RNA polymerase (RdRp) formed by PA, PB1 and PB2. This structure is the viral 
ribonucleoprotein complex (vRNP)32–34 and is represented figure 1.2b. Ultrastructure 
inspection of transverse sections of virions highlighted the state of organization of 
segments that are arranged in the ‘7+1’ conformation31, shown in figure 1.2c. 
 
Despite coding for different proteins, as depicted below in table 1.3, all viral 
segments share the same organization. vRNAs have a middle antisense coding region 
flanked by short untranslated regions (UTR) at both ends. These UTRs are highly 
conserved and show partial complementarity, which leads to base pairing. The double-
 
Figure 1.2. Influenza A virus. a) The viral particle has an envelope derived from the host lipid bilayer with surface proteins 
hemagglutinin (HA), neuraminidase (NA) and matrix protein 2 (M2). The core contains the segmented genome: eight 
segments consisting of negative-sense RNA coated with nucleoprotein (NP), and the viral polymerase complex
29
. b) Viral 
RNA is coated by NP at a ratio of 1NP:24nucleotides. The extremities are complementary and form a double-stranded 
structure, bound by the polymerase complex PA, PB1 and PB2. The segments adopt a cork-screw conformation with a loop 
region opposed to the polymerase
30
. c)  Transverse section of a viral particle, with vRNPs in a ‘7+1’ conformation
31
. Scale 
bar: 50 nm. 
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stranded RNA that originates comprises the promoter sites where the viral polymerase is 
bound35.  
The eight segments encode for 10 essential proteins and several accessory 
proteins, whose expression is cell-type and strain dependent. In relation to our model 
influenza virus: A/Puerto Rico/8/1934 (PR8) H1N1, expression of viral proteins 
characterized thus far are shown in table 1.3. 
 
Table 1.3. Genome segments and functions of coded peptides of H1N1 influenza A virus PR8 (A/Puerto 
Rico/8/1934)
36,37
. 
Segment 
Size 
(bp) 
Name of protein Main function Symbol 
Start-
stop 
(bp) 
Protein 
length 
(aa) 
1 2340 
Polymerase basic 
subunit 2 
5’-Cap recognition. PB2 28-2307 759 
2 2340 
Polymerase basic 
subunit 1 
RNA-dependent RNA 
polymerase. 
PB1 25-2298 757 
  Protein PB1-F2 Pro-apoptotic activity.* PB1-F2 119-382 87 
3 2230 
Polymerase acidic 
protein 
5’cap endonuclease  PA 25-2175 716 
  Protein PA-X 
Repression of RNApolI gene 
expression.* 
PA-X 25-784 252 
4 1780 Hemagglutinin 
Binding to surface receptors; 
endosomal fusion. 
HA 33-1733 565 
5 1570 Nucleoprotein 
Coating, nuclear export and 
replication of vRNAs. 
NP 46-1542 498 
6 1410 Neuraminidase 
Cleavage of HA-receptor 
binding. 
NA 21-1385 454 
7 1030 Matrix protein 1 
Matrix protein, nuclear export 
of vRNPs and viral budding. 
M1 26-1007 252 
  Matrix protein 2 Cytoplasmic vRNP release. M2 26-784 97 
  Matrix 42 
Replaces M2 in adamantine 
containing media.* 
M42   
8 890 Non-structural protein 1 
Inhibition of interferon 
response. 
NS1 27-719 230 
  
Nuclear export protein or  
Non-structural protein 2 
vRNP nuclear export, along 
with M1 and NP. 
NEP or 
NS2 
27-864 121 
*Auxiliary proteins. 
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1.3. Influenza A – replication cycle 
A summarized overview of the viral lifecycle is depicted in figure 1.3. IAV enters the 
cell in an endosome and upon viral disassembly it releases its segmented genome to the 
cytoplasm. The eight segments are transported to the nucleus where they undergo 
transcription and replication. After de novo synthesis of viral genome and proteins, viral 
components are transported through the cytoplasm to the plasma membrane, where a 
new particle is assembled and buds out of the cell. The lifecycle can therefore be divided 
into viral entry, transcription and replication, and assembly which will be discussed in more 
detail below. 
  
 
Figure 1.3. Influenza A virus replication cycle.  IAV enters cells by endocytosis after binding of the viral protein HA to 
sialic acid residues at the plasma membrane. Following internalization, endosomal acidification results in the fusion between 
the virion and endosomal membranes, releasing vRNPs to the cytoplasm. After translocation of vRNPs into the nucleus, 
transcription and replication occurs, and new segments are exported to the cytoplasm. vRNPs accumulate near the 
microtubule organizing center, are loaded onto Rab11 vesicles and are transported through the recycling endosome toward 
the assembly sites at the plasma membrane. Each of the segments is then incorporated into a budding particle created with 
host membranes decorated with HA, NA and M2, and inwardly with M1.  Illustration by MJ Amorim, unpublished. 
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1.3.1. Viral entry, disassembly and nuclear import  
The virus enters cells through receptor-mediated endocytosis, via interaction of the 
viral protein HA with molecules of sialic acid present in glycoproteins at the cell surface38.  
The viral particle is endocytosed in both clathrin-coated and uncoated vesicles, indicating 
a versatility in the internalization routes39. During this process, the virus is transported from 
early to late endosomes, in actin and microtubule-dependent processes40,41. For releasing 
its contents, IAV exploits the endosomal system (figure 1.4) where the increasingly acidic 
pH, caused by the activity of ATPases during endosome maturation, triggers a 
conformational change in HA causing fusion of endosomal and viral membranes42. At this 
point, the low pH activates the proton pump activity of the viral protein M2 to acidify the 
virus inner core leading to the uncoating of the viral particle. This acidification contributes 
to weakening the affinity between matrix protein M1 and vRNPs, resulting in vRNP release 
to the cytoplasm43.  
 
Figure 1.4. Viral entry by IAV. The virus enters cells by receptor-mediated endocytosis, by the binding of HA to sialic acid 
molecules present at the cell surface. Upon internalization, the increasingly acidic pH triggers a conformational change in HA 
causing fusion of endosomal and viral membranes. Afterwards, the increasing acidity spreads to the innercore of the particle, 
leading realtease of vRNPs to the cytoplasm.  At this point, vRNPs move across nuclear pores into the nucleus to undergo 
transcription and replication
44
.  
 
vRNPs are then imported to the nucleus33,45 to undergo transcription and 
replication.  All vRNP proteins contain nuclear localization signals, but at this point, each 
segment relies only on the localization signals on NP to enter the nucleus46. Due to their 
large size, viral segments cannot diffuse passively, requiring passage through the nuclear 
pore, a process that relies on interactions with members of the importin superfamily: 
importins α1 and α547.  
 
  
FCUP 
The role of ADP-ribosylation factor-like 15 in influenza A virus infection 
11 
 
 
1.3.2. Genome transcription, replication and nuclear export 
After nuclear import, negative sense vRNAs are the templates for production of 
both mRNAs to synthesize viral proteins and complementary RNA, the molecule that 
serves as template for de novo vRNAs synthesis48.  
Transcription is performed by the viral RdRp, resulting in 5′-capped and 3′-
polyadenylated mRNAs49,50. However, both modifications, that occur to most cellular 
mRNAs, are attained by different mechanisms. Transcription begins with ‘cap-snatching’ of 
host-capped mRNAs (figure 1.5), a process mediated by the subunit of the viral 
polymerase PB2 that binds cellular mRNA 5’cap structures and presents these mRNAs to 
the subunit PA that cleaves them 10-13 nucleotides downstream51. Besides mimicking 
host mRNA in the cellular environment and being advantageous during translation, this 
structure also acts as a primer for polymerization of viral mRNA by the viral encoded 
RdRp. Elongation of viral mRNA (mRNA) proceeds by viral PB1, until it reaches a short 
polyU sequence located almost at the end of each segment52. Here, template RNA slips as 
the polymerase codes a longer polyA tail than its coding sequence by a stuttering 
mechanism53,52 until it is released. The viral mRNA thus is an incomplete complementary 
copy of vRNA as it terminates ~17 nucleotides upstream of the end of the RNA segment54.  
 
Figure 1.5. Events during IAV genome transcription. Each viral segment, bound to their own RdRp, starts by binding the 
5’cap structures of cellular mRNAs via PB2. Then, PA cleaves the cap structure along with 10-13 nucleotides downstream, 
using it to prime the transcription of its viral mRNA. The elongation stage, performed by PB1, decelerates as the polymerase 
reaches a short polyU sequence at the 5’ terminus of each segment. Due to a stuttering mechanism, a polyA sequence is 
synthesized with superior length than its own coding template. mRNAs from viral origin have similar modifications to cellular 
ones, but these are a result of different mechanisms. Adapted from
55
. 
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As mentioned above, table 1.3 shows the viral proteins expressed from each 
segment upon infection with PR8. Several segments are capable of producing more than 
one protein, a diversity that is strain and cell-specific, and attained by different 
mechanisms. These mechanisms, indicated in figure 1.6, include: 1) multiple open reading 
frames (ORF), 2) alternative splicing or 3) ribosomal frameshift. This diversity increases 
the coding capacity of each vRNA for additional functional proteins. For instance, segment 
2 has two different ORFs, one coding for viral polymerase subunit PB1 and another coding 
for the much smaller viral protein PB1-F2 (figure 1.6). While PB1 is the viral RNA 
polymerase, PB1-F2 has a different function. Expressed solely in specific cells, it localizes 
to the mitochondria and induces cell death56.  Another example includes transcripts 
originating from segments 7 and 8 that can be alternatively spliced, a process that is 
accomplished by the host spliceosome complex. The alternatively spliced transcripts, M2 
and NEP, obtained from segment 7 and 8, respectively, exist in lower abundance, than its 
intronless counterparts that code for M1 and NS148. Another example of diversity is 
illustrated by segment 3 where a ribosomal frameshift results in a second protein PA-X57. 
The relevance of this protein is still to be understood, although mutant viruses lacking the 
peptide show reduced levels of replication and pathogenicity58. Other proteins have been 
identified, but require characterization during infection (M4237, PA-N155 and PA-N18258). 
Upon translation, several viral proteins are translocated to the nucleus, including 
the viral polymerases and NP, necessary to form the progeny vRNPs34.   
 
Figure 1.6. Representation of IAV proteins organized by segment. Variant proteins are noted with the corresponding 
molecular mechanism
59
. 
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As soon as there is a sufficient amount of vRNP-forming proteins, viral replication 
starts. The replication of the viral genome involves the synthesis of the intermediate, 
positive-sense, full length and complementary RNAs (cRNAs), that serve as templates for 
progeny vRNA synthesis, see figure 1.7a and b. Following synthesis, vRNPs need to be 
exported from the nucleus to reach the sites of virion assembly. Proteins M1 and NEP 
have nuclear localization signals and are responsible for nuclear export of vRNPs. These, 
along with vRNPs, organize a daisy-chain structure of vRNP-M1-NEP60,61, and are carried 
to the cytoplasm through the cellular CRM1-dependent pathway62–64.  
The exit of de novo segments from the nucleus is not concomitant to segment 
replication. In fact, the virus has developed a way of timing the export from the nucleus by 
controling the amount of the NEP65. Only  10-15% of segment 8 transcrips code for NEP 
as a result of a weak splicing site which delays the synthesis and accumulation of the 
protein66,67. The remaining 85-90% of transcripts code for viral NS1 earlier in infection, that 
among other functions blocks interferon response68. This inhibition will allow vRNPs to 
better escape viral RNA host sensors on the way to the plasma membrane. 
 
 
Figure 1.7. Replication of the viral genome. a) Schematic representation of viral replication. The viral genome synthesizes 
an intermediary positive-sense segment, in order to produce progeny negative-sense vRNP, in a second round of replication. 
b) Formation of ‘nascent’ vRNPs. Electron microscopy micrographs of negatively stained purified RNP with branched 
appearance
69
.  
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1.3.3. Transport of the viral genome, assembly, budding and particle release 
After nuclear export, the viral genome needs to reach the plasma membrane,  
where the viral particle assembles and buds out of the cell32,34.  
As summarized in figure 1.8a, the transport of vRNPs is at least a two-step 
process: first, in the proximity of the microtubule organizing center, vRNPs attach  to 
vesicles bearing the small GTPase Rab1170, a recycling endosome marker. Work by 
Kawaguchi and colleagues suggests that cytoskeleton-interacting protein YB-1 stimulates 
the delivery step of vRNPs to the recycling endosome71. Second, they are translocated 
using, in part, the microtubule network towards the plasma membrane. This way, vRNPs 
are directed from the perinuclear area through the recycling endosome, bound to Rab11 
vesicles on route to the cell periphery. This process can be blocked by a drug called 
nucleozin72, that “staples” NP molecules between different vRNPs, resulting in cytoplasmic 
aggregation of vRNP-Rab11-carrying vesicles73, figure 1.8b. For detailed description on 
the mode of action of nucleozin see72,73. 
Packaging of the eight segments, which is a necessary step to the production of 
infectious particles, does not seem to operate by a random mechanism74,75 as production 
of infectious virions is more efficient than the 1/416 probability of combining eight 
A 
 
B 
 
Figure 1.8. vRNP transport to the plasma membrane. a) After de novo synthesis and nuclear export, vRNPs are carried 
thorough the recycling endosome in Rab11-positive vesicles towards the plasma membrane
70
. b) Effects of nucleozin 
treatment in infected cells. Cytoplasmic vRNP (NP) aggregation co-localizes with Rab11 at 8 hours post infection in treated 
cells
73
. The drug added at 6 hours post infection at 1µM. Scale bar: 10µm. 
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segments by chance76. Furthermore, the equimolar concentration of each segment in viral 
particles77  even with unproportioned amounts in infected cells78, reinforces the “selective 
packaging” model. The mechanism behind segment selection has been widely addressed 
and vRNP assembly has been suggested to occur directly by RNA-RNA interactions or 
through an unidentified protein intermediate74 (figure 1.9a and b).  
Literature postulates that different vRNP segments are carried together to the 
plasma membrane, still in a Rab11-dependent manner. In particular, studies by Chou et 
al.79 and Lakdawaka et al.80 proposed a model where vRNAs assemble on the way to the 
plasma membrane. They observed fusion/scission events between vesicles carrying 
vRNPs which resulted in co-localization of different segments. This raised the hypothesis 
that the recycling endosome may facilitate the assembly of the eight segments to be 
included in a virion, as illustrated by figure 1.9d. 
A RNA-RNA             B RNA-X-RNA 
 
 
 
C 
Figure 1.9. Selective packaging of IAV segmented genome. The assembly of a vRNP complex, containing each of the 
eight vRNAs, may be mediated by a) RNA-RNA interactions perhaps involved in secondary structures or b) by an 
intermediate host protein factor (X)
74
. c) Assembly and transport of vRNP complexes through the recycling endosome in 
Rab11 vesicles.  Adapted from
81
. 
Our group has evidence that the vRNP binding to Rab11 vesicles competes with 
the standard ligation of Rab11-interacting proteins, FIPs, and causes “slowing down” in 
recycling efficiency (figure 1.10). In support, using correlative light and electron microscopy 
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our lab observed the coalescence of vesicles, resulting in enlarged aggregates 
(unpublished data). Such agglomeration of vesicles carrying different vRNPs allows for the 
close contact of segments, perhaps facilitating intersegment interaction. This notion 
agrees with previously established theories regarding the formation of vRNP super-
complexes before reaching the plasma membrane, reviewed in81. In conformity, our data 
shows that transferrin recycling is impaired in infected cells, supporting a direct 
competition between Rab11 effectors and vRNPs.  
 
 
Figure 1.10. vRNP outcompete FIPs on the binding to Rab11, causing cytoplasmic agglomeration of vesicles 
carrying the viral genome. a) In non-infected cells, Rab11 binds to FIPs, allowing transport of these vesicles by molecular 
motors along the microtubule network. Whereas in b) infected cells, vRNPs outcompete FIPs, resulting in the cytoplasmic 
accumulation of vRNP containing vesicles. This event is thought to promote intersegment contacts, presumably aiding 
super-complexes formation, which are incorporated into a viral particle. Illustration by MJ Amorim, unpublished.  
 
Regardless of whether in a complex or isolated, vRNPs need to meet the 
remaining viral proteins that localize beneath or at the plasma membrane. Viral assembly 
occurs at specific sphingolipid-enriched regions, called lipid rafts32. These are able to limit 
protein diffusion, operating as functional domains for example by harboring many proteins 
involved in signaling cascades82. Viral envelope proteins HA and NA are targeted to these 
regions, conversely to M2, which is resides in regions flanking lipid rafts83. The viral protein 
M1, mentioned above to participate in the nuclear export of vRNPs, also ensures that 
vRNPs do not return to the nucleus84. Furthermore, it has also been suggested that M1 
plays a part in particle assembly by bridging the virion core to the envelope, especially the 
viral protein M285, although binding to HA and NA might also occur86. However, the means 
by which M1 is transported to the assembly sites remains undescribed.  
The process of viral budding is still unclear, but requires the following steps: 1) 
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induction of membrane tension and curvature leading to the formation of a bud, 2) 
elongation of the particle, and finally 3) recoiled membrane curving resulting in membrane 
scission and release of the particle26. It is generally agreed that curvature is facilitated by 
binding of the matrix protein M1 to the cytoplasmic tails of envelope proteins HA and NA 
microdomains, although binding domains between these proteins remain to be 
identified34,87. This is thought to induce stiffness in the membrane, resulting in a small 
curvature34,88. Of note, each one of these proteins has individually produced viral-like 
particles in in vitro assays, suggesting a synergistic role in promoting viral budding and 
release34. Subsequently, the bend may be elongated by the action of M1, which also 
associates with the viral genome60, perhaps prompting segment packaging. Lastly, ion 
channel M2, which is excluded from lipid-rafts, has an important role forming a neck 
structure by the  insertion of an amphipathic helix into the lipid bilayer resulting in scission 
of membranes34. This process of scission is, in many enveloped viruses, attributed to 
host’s ESCRT proteins. However, IAV bypasses the need for ESCRT proteins, being only 
mediated by viral M289.  
There are however several other host factors that have been suggested to 
influence the budding process. Among these are: F1Fo ATPase, thought to influence 
membrane bending by contributing with mechanical energy by hydrolysis of ATP90; actin 
modulating protein Cofilin-1 by influencing cytoskeleton organization needed for efficient 
budding91; RACK1, shown to be involved in cytokinesis and to bind the viral protein M1 to 
facilitate viral release92; Annexin-A6 involved in cholesterol homeostasis that was 
suggested to affect viral release93; and CD81, involved in signal transduction, whose 
depletion resulted in abnormally elongated virions attached to the plasma membrane94.  
To be released, the virus requires a couple of significant last steps to complete its 
life cycle. Firstly, it needs the action of the viral envelope protein NA to cleave the HA-sialic 
acid bond established at the cell surface during budding95,96. After particle release, the 
virus undergoes one last step of maturation, by cleavage of viral protein HA by 
extracellular proteases97,98. Without this modification the next round of infection would be 
unsuccessful, as HA would not mediate membrane fusion between endosomal and virus 
membranes upon entry97.  
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1.4. Cellular secretory pathway and vesicle trafficking 
As an obligatory intracellular parasite, viruses typically highjack cellular machinery 
and pathways to complete their replication cycle. In the case of IAV, the cellular secretory 
pathway is indispensable for assembly of progeny virions70,99, as most viral components 
reach the plasma membrane on account of this system to assemble into a particle.  As 
described in the previous section, the newly-synthesized viral genome, in form of vRNPs, 
is loaded onto Rab11 vesicles and carried to the plasma membrane70. Rab11 is a major 
regulator of the recycling endosome.  This organelle consists of networks of tubules of 60 
nm wide that emanate from the microtubule-organizing center, transporting endocytosed 
or newly synthesized molecules to the plasma membrane100. Figure 1.11 shows the 
communication web of the recycling endosome with the remainder of the secretory 
pathway. Recycling receives material from the early endosome and also from the trans 
Golgi network (TGN).  
Protein sorting is carefully regulated with high specificity. Events of mistargeted 
proteins are the basis of many neuropsychiatric, endocrine and metabolic disease 
pathogenesis101. Secretory pathway dynamics are coordinated mostly by small GTP-
binding proteins102,103. This superfamily has hundreds of known proteins divided into five 
families: Ras, Rho, Ran, Rab and ADP-ribosylation factors (Arf); the nomenclature 
guidelines indicate that all-capital letters should be solely used when referring to human 
Arf proteins. In a simplistic way, the Ras family is generally responsible for cell 
proliferation, Rho for cell morphology, Ran for nuclear transport and, the focus of our work, 
Rab and Arf proteins for vesicle transport102.  
 
Figure 1.11. Rab11 as the major regulator of the 
Recycling Endosome. Rab11 orchestrates the 
molecule transport originating from the trans Golgi 
network (TGN), early or late endosomes (EE, LE) 
towards the plasma membrane, routes highlighted in 
green. Adapted from
100
. 
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In the context of vesicular trafficking between organelles, Rab proteins are thought 
to dictate the destiny of the cargo. Every other event needed to achieve the formation of a 
vesicle, requires the participation of many other molecules, recruited or removed by a 
complex and dynamic flow operating in sequential order.  
In very simplified terms, that are depicted in figure 1.12, a budding vesicle starts 
forming in a donor compartment, composed of specific lipids as a result of the activity of 
lipid modifying enzymes104. These work as docking platforms for Arf family activating 
proteins, the guanine nucleotide exchange factor (GEF)105. Each GEF protein activates its 
corresponding Arf by switching GDP to GTP, a process described later on. Arfs recruit 
coating molecules to the surface of the budding vesicle, cargo from the cytoplasm and 
RabGEF proteins able to recruit and activate Rabs, constituting a signaling cascade of 
events106. Each organelle has a specific set of Rab proteins that dictate its identity and 
consequent function107. Subsequently, Rabs are in turn able to attract molecular motors 
that transport vesicles along the cytoskeleton to acceptor membranes, where they fuse108. 
Tethering factors are responsible for attachment of vesicles to membranes, as other 
proteins facilitate fusion between vesicles and the target membrane, collectively called 
SNAREs109. 
 
Figure 1.12. Biogenesis process of a vesicle during intracellular trafficking. Vesicle formation involves a series of 
sequential steps with the intervention of several classes of proteins. Phosphoinositide kinases modify lipids able to anchor 
and recruit proteins necessary for vesicle formation. Initially, ARF/ARLs recruit coating and scission factors as well as cargo. 
Then, Rabs are responsible for attraction to motors, tethering, docking, fusion of vesicles with the donor 
compartments/membranes
110
.  
 
Interestingly, some RabGEFs were found to be recruited by Arf GTPase activating 
proteins (Arf-GAPs)111, some ARFs by Rab effectors112 and some ARFs attracting lipid-
modifying enzymes113, suggesting a more complicated network of interactions between all 
these individually described family of proteins.  
The highjack of the recycling endosome by IAV can be inhibited by depleting cells 
from Rab11, with severe effects on viral production. Given the complexity of the secretory 
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pathway, it is anticipated that other host factors are involved in the trafficking of Rab11 
vesicles, thus affecting vRNP transport towards assembly sites. 
The ARF family is a subset of the small GTPase superfamily with important roles in 
vesicular traffic, as described below. In total, it comprises: 5 ARFs, 21 ARF-Like proteins 
(ARLs), two SAR1 isoforms, a ARF-related protein 1 (ARFRP1) and TRIM protein 23 in 
humans114–116. 
ARF proteins acquired their name on account of their role as co-factors in the 
catalysis of ADP ribosylation, by the cholera toxin117. Currently, the ARF reference is kept, 
but only ARFs share the co-factor capacity for the toxin action, as the remaining members 
of the family do not promote ADP ribosylation118. Instead, ARLs and SARs are part of the 
ARF-family not based on specific functions, but due to sequence comparison and structure 
similarity.  The sub-category of ARLs arose from the discovery of hypothetical ARF 
sequences with identity below 60%, that lacked the co-factor activity for cholera toxin and 
were unable to rescue lethal mutants of arf1- and arf2- deletion in S. cerevisea115,118. 
Additionally, SAR1 was one of the earliest members of this family, with a name derived 
from its identification as a secretion-associated Ras-related protein. In comparison to 
ARFs, SAR1 isoforms present a sequence identity inferior to 30%118. 
Consistent with the remaining small GTPases, ARF-family proteins generally are 
able to interconvert from an inactive GDP-bound to an active GTP-bound state and to bind 
specific effectors while in the “on” or “off” status. The GDP/GTP switch is generally very 
slow, requiring catalysis by GEFs, as mentioned and although belonging to the small 
GTPase superfamily, have a negligible GTPase activity and rely on GAPs to be 
inactivated115,119. 
ARF-family proteins share distinct signatures in its amino acid sequence, 
associated with functional domains. Firstly, they have an N-terminus amphipathic helix that 
undergoes post-translational modifications, functioning as an anchor to membranes when 
the protein is activated by GEFs115,120 (figure 1.13a and c).  
Secondly, members from the ARF-family have specific domains, which change 
configuration upon activation/inactivation, termed switch-1 and switch-2 (figure 1.13b). 
These regions flank a two β-strand interswitch domain, which ultimately rearranges switch 
1 and 2115,119. In its GDP-bound inactivated state, the protein is soluble due to the N-
terminus helix being packed into a hydrophobic groove on the opposite side of the protein. 
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Here, an aspartate residue of the interswitch mimics the charge of GTP, preventing the 
binding of the molecule. Upon activation with a GEF, the strands of the interswitch slide 
pulling switch 1 and 2 ‘up’ and projecting out the amphipathic helix119,121. Simultaneously, 
the switch regions acquire the GTP-binding conformation, resulting in an activated protein, 
with an exposed helix to bind membranes. Membrane dissociation occurs spontaneously 
upon GTP hydrolysis, upon the action of a GAP116.  
Exceptions include ARF6, which remains membrane-bound in its off-state, perhaps 
interacting with other membrane-localized partners mediating signaling122.  
Thirdly, the spacer sequence between the helix and the remaining ARF is rather 
short in comparison with the one from Rabs or Rhos, placing them in closer proximity to 
membranes in its activated state115,116. This feature was initially associated with the 
participation of ARFs in vesicle biogenesis, having coat proteins or lipid modifying 
enzymes as effectors, shaping or attracting the bilayer surface116,123. This participation in 
the early steps of vesicle budding, also shared by SAR1 isoforms, has been broadened to 
include additional functions such as involvement in: microtubule dynamics (ARL2124,125), 
cell cycle progression (ARL3126) or to influence organelle positioning (ARL8127).  
 
Figure 1.13 Activation cycles of ARF proteins. a) GDP/GTP bound alternative conformations of ARF1
118
 and mechanisms 
of interaction with ARF GEFs or GAPs
115
. b) Domains conserved in ARF/ARLs
115
. c) GTP-bound conformation involves 
recruitment to a specific membrane
115
.  
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Given their importance in membrane traffic regulation, our aim is to identify 
members of the ARF-family of proteins involved in the trafficking of the viral genome 
towards the plasma membrane and to characterize their role in this process. 
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1.5. Objectives of the work  
Infections due to IAV in humans cause disease of variable outcomes including 
excess death rates. Existing strategies aim to prevent epidemics and pandemics with 
vaccination and mitigate the effects of infections with drugs that inhibit viral proteins. 
However, antiviral medication leads to the emergence of drug-resistant escape mutants, 
rendering inefficient the scarce amount of treatments available for IAV infection. Thus, 
novel antivirals are needed. An alternative approach to targeting viral proteins in IAV 
therapy would be to inhibit key host processes involved in viral replication. Blocking the 
activity of cellular proteins or its interaction with the virus requires in-depth knowledge of 
host-pathogen interactions. 
The assembly of virions is a crucial step in the viral lifecycle. In particular, the 
transport of the viral genome to assembly sites has, as explained in the introduction, 
emerged as key in viral replication for a variety of reasons. The recycling endosome, and 
its major regulator Rab11, were found to influence this process, but no other host proteins 
were identified. The secretory pathway is notorious for its complexity, with specific 
networks of proteins securing vesicular biogenesis, transport and delivery to precise 
destinations. This complexity makes it unlikely that Rab11, the only protein thus far 
implicated in the process, may coordinate trafficking of vRNPs alone. One of the most 
prominent families that regulate the secretory pathway is the ARF-family. The goal of this 
project is to expand on host requirements for the recycling endosome and identify which 
ARFs are important for viral infection. 
To this end, an initial screen, herein described in the preliminary data section, 
identified a promising candidate to influence IAV infection: ARL15.  The aim of this work is 
to characterize the role of ARL15 during infection with IAV. This thesis is divided into two 
main subchapters of results where the following topics will be assessed: 
I. The effect of ARL15 depletion on IAV production;  
II. The levels, intracellular distribution and function of ARL15 during IAV infection. 
Altogether, this study aims to identify novel host-factors involved in IAV infection 
and shed some light on the mechanisms that lead to an efficient assembly of IA virions. 
This constitutes the first step in understanding whether a specific pathway could be 
targeted for antiviral therapy.  
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CHAPTER 2 | Materials and methods 
 
Table 2.1. Reagents. Primary and secondary antibodies, siRNAs, plasmids, transfection and cloning reagents used 
in the procedures described below. 
Primary 
Antibodies 
Brand, Reference Host Dilutions 
ARL15 ProteinTech®, #11934-1-AP Rabbit  Western blot: 1:500 
Immunofluorescence: 1:100 
GAPDH Sicgen®, #AB0049-200 Goat  Western blot: 1:2000 
GBF1  BD transduction Lab®, #612116 Mouse IgG1  Immunofluorescence: 1:500 
GFP Sicgen®, #AB0066-200 Goat  Western blot:1:5000 
HSP 60 AbCam®, #ab31115 Rabbit  Immunofluorescence: 1:200 
Myc  AbCam®, #ab9132 Goat  Western blot: 1:500 
NP (Ms) AbCam®, #ab20343 Mouse IgG2a  Immunofluorescence: 1:2000 
NP (Rb) Homemade, in
70
  Rabbit  Western blot: 1:1000; 
Immunofluorescence: 1:1000 
Rab11 Invitrogen®, #715300 Mouse  Immunofluorescence: 1:100 
TOM 20 Sigma®, #WH0009804M1 Mouse IgG1  Immunofluorescence: 1:100 
    
Secondary Antibodies Brand, Reference  Host Dilutions 
Alexa Fluor® Anti-Rabbit 488 
Life technologies®, 
#A-11008 
 Goat 
Immunofluorescence: 
1:1000 
Alexa Fluor® Anti-Mouse 488 
Life technologies®, 
#A-11001 
 Goat 
Immunofluorescence: 
1:1000 
Alexa Fluor® Anti-Mouse IgG2a 488 Life technologies®, 
#A-21131 
 Goat Immunofluorescence: 
1:1000 
Alexa Fluor® Anti-Rabbit 568 
Life technologies®, 
#A-21069 
 Goat 
Immunofluorescence: 
1:1000 
Alexa Fluor® Anti-Rabbit 568 
Life technologies®, 
#A-21069 
 Goat 
Immunofluorescence: 
1:1000 
Alexa Fluor® Anti-Mouse IgG1 647 
Life technologies®, 
#A-21240 
 Goat 
Immunofluorescence: 
1:1000 
IRDye 800CW Donkey Anti-Goat Li-Cor®, #926-32214  Donkey Western blot: 1:10 000 
IRDye 800CW Donkey Anti-Rabbit Li-Cor®, #926-32213  Donkey Western blot: 1:10 000 
IRDye 680RD Donkey Anti-Rabbit Li-Cor®, #926-68073  Donkey Western blot: 1:10 000 
    
siRNAs Brand, Reference Concentrations 
siNT (Non-targeting) Quiagen , #SI1022076 Final concentration: 25nM 
siARL15-1, -2, -3 Quiagen , #SI04160366; #SI04165098; 
#SI04206258 
Final concentration: 25nM 
siGFP Quiagen , #SI04380467 Final concentration: 25nM 
   
Transfection Reagents Brand, Reference Concentrations 
Lipofectamine® 2000 Life technologies®, #11668027 Final concentration: 0.15% (v/v) 
Lipofectamine® LTX Life technologies®, #15338100 Final concentration: 0.10% (v/v) 
DharmaFECT-1 Dharmacon®, #T-2001 Final concentration: 0.20% (v/v) 
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(continuation of Table 2.1) 
Cloning 
Reagents 
Brand Specifications 
Primer A1 Eurofins Forward primer, with an AgeI restriction site and the 
initial coding sequence of ARL15. (5’accggtatgtctgat 
ctccga) 
Primer A2 Eurofins Reverse primer, with a BamHI restriction site and the 
terminal ARL15 coding sequence followed by a myc 
tag. (5’ ggatcccagatcctcttctgagatgagtttttgttccattcttacag 
cttc) 
Primer B1 Eurofins Forward primer, with an AgeI restriction site and a 
myc-tag followed by the initial coding sequence of 
ARL15. (5’accggtatggaacaaaaactcatctcagaagaggatc 
tgatgtctgatctccga) 
Primer B2 Eurofins Reverse primer with a BamHI restriction site and the 
terminal coding sequence of ARL15. (5’ ggatcctcaca 
ttcttacagcttcatggtc) 
Primer C1 Eurofins Forward primer with a BamHI restriction site followed 
by initial coding sequence of Bcl-2 mitochondrial 
sorting signal. (5’ ggatccttctcctggctgtctctgaa) 
Primer C2 Eurofins Reverse primer with the terminus coding sequence of 
Bcl-2 mitochondrial sorting signal followed by a 
BamHI restriction site. (5’ ggatcctcacttgt 
ggcccagatagg) 
   
AgeI New England Biolabs, 
#174R0552S 
10 units per reaction 
BamHI New England Biolabs, 
#174R3136S 
10 units per reaction 
NheI New England Biolabs, 
#174R0131S 
10 units per reaction 
   
Quick Ligase New England Biolabs, 
#174M2200L 
10 units per reaction 
   
NZY miniprep kit NZYtech, #MB01002 Used according to manufacturer’s instructions 
   
Plasmids  Description  Source 
pGFP pEGFP-N1 with resistance to kanamycin, expressing an 
EGFP fluorescent tag under a CMV promoter.  
Invitrogen© 
pARL15-GFP ADP Ribosylation factor 15 coding sequence, in a 
pEGFP-N1 backbone, with resistance to kanamycin, 
expressing ARL15 with a C-terminal fluorescent tag, 
under a CMV promoter. 
Kindly given by J 
Mota – ITQB 
pARL15-myc ADP Ribosylation factor 15 coding sequence, in a 
pEGFP-C1 backbone, with resistance to kanamycin, 
expressing ARL15 with a C-terminal myc tag, under a 
CMV promoter.  
A Nascimento 
pMyc-ARL15 ADP Ribosylation factor 15 coding sequence, in a 
pEGFP-C1 backbone, with resistance to kanamycin, 
expressing ARL15 with a N-terminal myc tag, under a 
CMV promoter.  
A Nascimento 
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(continuation of Table 2.1) 
pMitoCherry Tom20 mitochondrial sorting signal cloned in the N-
terminus of mcherry in pmCherry-C1 plasmid with 
resistance to kanamycin, under a CMV promoter. 
M Alenquer – 
CBV, IGC 
pMitoRab11a-DN Tom20 mitochondrial sorting signal cloned in the N-
terminus of pCherryRab11a-DN plasmid with resistance 
to kanamycin, under a CMV promoter. Rab11a has with 
single substitution in S25N. 
A Seixas – CBV, 
IGC 
pMitoRab11a-
WT 
Tom20 mitochondrial sorting signal cloned in the N-
terminus of Rab11 in pCherryRab11a-WT plasmid with 
resistance to kanamycin, under a CMV promoter. 
A Nascimento 
pARL15-myc-
mito 
Bcl-2 mitochondrial sorting signal cloned in the C-
terminus of ARL15-myc sequence of pARL15-myc, with 
resistance to kanamycin, under a CMV promoter. 
A Nascimento 
pSAR1A-GFP 
pSAR1B-GFP  
Coding sequence of Secretion-Associated Ras proteins A 
and B isoforms (Sar1A and Sar1B) inserted in pEGFP-
N1, with resistance to kanamycin, under a CMV promoter. 
B Kellen – CBV, 
IGC 
Plasmids expressing the coding sequence of: ARF1,  ARF3, ARF4, ARF5, 
ARF6, ARL1, ARL2, ARL3, ARL4A, ARL4C, ARL4D, ARL5A, ARL5B, ARL8A, 
ARL8B, ARL9, ARL10, ARL13B, ARL14, ARL16 and ARL17), ARF-related 
protein 1 (ARFRP1), and tripartite motif-containing protein 23 (Trim23) under a 
CMV promoter, inserted in a pEGFP-N1 backbone (GFP tag on the C-
terminus) and resistance mark to kanamycin. 
Kindly given by J 
Mota – ITQB 
 
Cell Lines | Different cell lines were used according to specific purposes. HeLa cells, 
originated from cervix adenocarcinogenic epithelia, are easy to transfect and suitable for 
immunocytochemistry assays, due to their expanded shape. Madin-Darby canine kidney 
(MDCK) epithelial cells have high adherence to substrate. Therefore, MDCKs are more 
resistant to the presence of trypsin, and were used in assays involving viral titration by 
plaque formation. Human alveolar basal epithelial (A549), originating from lung carcinoma, 
were used as an ex vivo model for IAV infection. Human embryonic kidney 293T (HEK 
293T) epithelial cells were used when high transfection efficiency was required.  
Stable Cell Lines | A549 and HEK 293T cells were transduced individually with lentivirus 
encoding GFP tagged ARL15, Rab11a WT or Rab11a variants containing the point 
mutations Q70L(constitutively active (CA)) or S25N (dominant negative (DN)). These 
stable cell lines will be henceforward addressed as ‘ARL15-GFP’, ‘GFP-Rab11a-WT’, 
‘GFP-Rab11a-CA’, ‘GFP-Rab11a-DN’, respectively. As background, a control cell line 
expressing GFP protein was established, and will be designated ‘GFP’ stable cell line 
throughout the text. 
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Cell Culture |  All cell lines were cultured accordingly to128 in Dulbecco Modified Eagle 
medium (DMEM) (Life Technologies), supplemented with 10% fetal bovine serum (V/V), 
200 mM glutamine, 100 U/ml penicillin and 10 µg/ml streptomycin. Stable cell lines 
described above were also supplemented with 1.25 µg/mL puromycin for positive 
selection. Whenever mentioned, nucleozin, diluted in DMSO, was added at 2µM.  
Infection | All infections were carried out with reverse genetics-derived A/Puerto Rico/8/34 
(PR8; H1N1)129 produced as in130. PR8 was added at the multiplicity of infection (MOI) 
specified in each case, in serum-free DMEM (Life Technologies) or in OptiMEM Reduced 
Serum Media (Life Technologies) in case of infection of transfected cells. After 30 min of 
infection, cells were overlaid with serum free DMEM media supplemented with 0.14% (w/v) 
bovine serum albumin (BSA).  
siRNA silencing | 10⁵ A549, or A549 stably expressing ‘ARL15-GFP’ or ‘GFP’ were 
transfected with Flexitube siRNA (Qiagen) targeting: ‘GFP’ (SI04380467), and/or the 3’ 
untranslated region of endogenous ARL15 (SI04160366, SI04165098, SI04206258), using 
Dharmafect-1 transfection agent according to manufacturer’s instructions. As a negative 
control, a non-targeting RNA (SI04380467) sequence was used. Cells were incubated at 
37⁰C and 5% CO2 for 36 hours prior to being infected with PR8 at a MOI of 5. Cells were 
harvested at 16h p.i. and processed for immunofluorescence, plaque assays and/or 
western blotting.  
Rescue Assays | 10⁵ HEK 293T cells were transfected for 36h with siRNAs targeting 
ARL15  or control siNT, concomitantly with 200 ng of the following plasmids: pARL15-myc, 
pARL15-GFP and pGFP using Lipofectamine®2000 according to manufacturer’s 
guidelines. Cells were infected with PR8 (MOI of 5) and incubated for 16 hours at 37⁰C 
and 5% CO2.  After this time, supernatants were collected for plaque assays and cells 
were lysed in Laemmli buffer for western blotting. 
Plasmid transfections | 10⁵ HeLa cells were transfected with 200ng of plasmid using 
Lipofectamine LTX, according to the manufacturer’s instructions, and incubated for 24h.  
Then cells were infected, as explained above, with indicated MOI and incubated for a 
referred period of time until being fixed in 4% PFA before immunofluorescence processing.  
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Plaque Assays | In order to quantify virus titers, a confluent monolayer of MDCK cells was 
infected with 1:10 serial dilutions of each supernatant sample (10⁻¹ to 10⁻⁶) in serum free 
media. One hour post-infection cells were overlaid with a solution diluted 1:2 in serum free 
media containing 4% Avicel, 0.14% BSA, 1µg/mL TPCK trypsin, and incubated at 37⁰C, 
5%CO2 for 36 hours. Then, cells underwent a fixation-staining step in a 4%PFA-0.2% 
toluidine blue solution. Virus titers were estimated as plaque forming units/mL (PFU/mL).  
Western Blot | Approximately 10⁴ cells kept in Laemmli buffer and separated by SDS-
PAGE, were transferred to a nitrocellulose membrane at 200 mA for 45 minutes. A two 
buffer system was used in stacks containing filter paper, the membrane and the gel: 
starting at the negative pole, 3 layers of filter paper soaked in 0.3M Tris and 20% (v/v) 
ethanol followed by 3 layers of 25mM Tris and 20% ethanol (v/v) were laid below the 
nitrocellulose membrane. Then, the acrylamide gel was placed over the membrane, 
followed by another 6 layers of filter paper in 25mM Tris and 20% (v/v) ethanol, under the 
positive pole. Upon transfer, membranes were blocked in 5% skimmed milk for 30 min in 
0.2% (v/v) tween-PBS (PBST). Then, membranes were incubated with primary antibodies 
against the proteins of interest for 1 hour followed by extensive washing in PBST. 
Membranes were then incubated with host-specific secondary antibodies conjugated to 
fluorochromes LiCor 800 or 680 for 30 minutes and washed three times in PBST. Both 
incubations were done at room temperature. Membranes were scanned using a LiCor 
Biosciences Odyssey near-infrared platform. 
Immunofluorescence | Approximately 10⁴ cells were seeded on 13 mm diameter glass 
coverslips (VWR), infected, and/or transfected as described above. Upon the time p.i. 
required, cells were fixed in 4% (v/v) paraformaldehyde for 20 minutes, washed in 0.5% 
(w/v) BSA-PBS and permeabilised in 0.2% Triton X-100-PBS for 7 minutes. Upon this 
time, cells were blocked in 0.5% (w/v) BSA-PBS. Primary antibody staining was performed 
against proteins of interest for 1 hour followed by secondary staining using host-specific 
conjugated antibodies Alexa 488, 647 or 568 incubated in the dark, for thirty minutes. 
Washes between stainings were performed thoroughly with 0.5% (w/v) BSA-PBS for 15 
minutes at room temperature to remove traces of unbound antibody. Coverslips were 
mounted using Dako© mounting medium. Confocal images were acquired on a Leica SP5 
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confocal using a 63x 1.3NA Oil immersion objective, and illuminated with Ar, HeNe or UV 
lasers. From fixation onwards, the procedure was carried out at room temperature. 
 Measurement of vesicular area | Confocal images stained with NP were analyzed using 
Fiji ‘Analyze Particles - Area’ tool. The output value of the area of each vesicle was used to 
calculate an average vesicular area per cell. The mean value per cell was plotted and 
evaluated for statistical significance using the methods described below. A minimum of 20 
cells were analyzed per condition.  
Co-localization analysis | Confocal images were analyzed using Fiji plugin 
‘Colocalization Finder’, to determine areas of overlap between indicated stainings. The 
output value of Pearson’s Correlation Coefficient was acquired for twenty cells per 
condition, plotted and evaluated for statistical significance. 
Statistical analysis | Results are expressed as mean ± standard error of the mean 
(SEM). Exceptionally and as indicated, dot plots containing measurements of either 
colocalization or vesicle size, were expressed as median, since these had already taken 
into account the average value per cell. D’Agostino Pearson test was performed to assess 
the normal distribution of values. Statistical significance analysis was conducted by the 
one way analysis of variance (ANOVA) or by unpaired t-test, with 95% confidence. 
Additionally, the Tukey test was used for multiple comparisons.  
Cloning | pARL15-myc was constructed using the PCR product of ARL15’s coding 
sequence amplified from the template pARL15-GFP, with primers containing the myc tag 
sequence and AgeI and BamHI restriction sites (Primers A1 and A2). Then, the construct 
was digested with AgeI and BamHI and inserted in a pEGFP-C1 (Invitrogen©) plasmid 
lacking the GFP tag. pMitoRab11aWT was cloned by removing TOM20 mitochondrial 
sorting signal from pMitoCherry with AgeI and NheI restriction enzymes and fusing this 
sequence to the N-terminus of Cherry-Rab11aWT in plasmid pCherryRab11aWT, upon 
digestion with the mentioned enzymes. pARL15-myc-mito was cloned in two steps: first, 
the Bcl-2 C-terminus mitochondrial sorting signal was amplified with PrimerC1 and C2 
containing BamHI restriction sites in both ends from HeLa genomic DNA. Second, the 
amplicon was digested with BamHI and fused to the C-terminus of the myc tag of the 
plasmid pARL15myc. 
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Upon vector ligation, plasmids were used to transform E. coli TOP10 by heat-shock. 
Bacteria were plated in plates with agarose-LB media supplemented with antibiotic specific 
to the plasmid and incubated at 37⁰C. Clones were screened for the presence of the insert 
by PCR and restriction digestions. Positive clones were purified using with NZYminiprep kit 
and then sequenced to confirm sequence integrity.   
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CHAPTER 3 | Results 
 
3.1. Validation of ARL15 as a host factor involved in IAV infection 
IAV genome encodes a modest number of proteins that are insufficient to sustain 
its replication without using host resources. It is therefore not surprising that viruses take 
advantage of many host cellular pathways and machinery during infection. In particular, 
the small GTPase Rab11 was shown to have a prominent role in IAV infection, 
transporting the viral genome to sites of assembly, and directly influencing viral 
production70,131–133. Besides Rab11, recycling is regulated by several other factors that 
ensure vesicle biogenesis, cargo loading, movement, vesicle delivery and fusion with 
precise membranes. Such accuracy is ensured by networks of regulatory, effector, motor, 
membrane tethering and fusogenic proteins that remain unidentified for the transport of 
IAV genome. ARFs have been described to have important roles in the secretory pathway, 
having mostly been defined as operating at the level of vesicle biogenesis, although 
recently additional roles have been described. Hence, the goal of this project is to identify 
proteins from the ARF-family that are involved in the genome trafficking step. 
 
3.1.1 Preliminary data: screening of proteins from the ARF-family required for 
vRNP trafficking during IAV infection 
To identify ARFs involved in IAV infection, an immunofluorescence-based screen 
was carried out by B Kellen prior to my arrival at the lab. It aimed to identify interactions 
between ARF proteins and vesicles carrying the viral genome via quantifying the areas in 
which these proteins occupied the same cellular space. Determining co-localization 
between ARFs and vRNP-Rab11 vesicles presented several challenges due to: 1) low 
endogenous levels of ARF-family proteins in cells, 2) limited number of available 
antibodies for their specific labelling and 3) fast turn-over of vesicular membranal contents, 
with short lived interactions between Rab11 and ARFs. To mitigate these problems, GFP-
tagged ARFs were overexpressed in cells treated with a drug previously shown to 
aggregate vRNP-Rab11 vesicles73, that was used to enrich vesicular content. This drug, 
FCUP 
The role of ADP-ribosylation factor-like 15 in influenza A virus infection 
32 
 
 
known as nucleozin, was first described by Kao and colleagues72, to display affinity for 
several domains of the viral protein NP even when this protein is coating viral RNA in 
vRNPs. At late times of infection, vRNPs are exported from the nucleus and are mostly 
attached outwardly to Rab11 vesicles. Here, nucleozin supplementation leads to vesicular 
“stapling” upon normal collision events that occur during transport, inducing the formation 
of dramatic cytoplasmic aggregates (figure 1.8b and 3.1b, middle panel).  
The screen was prepared as follows: GFP-tagged versions of ARF-family proteins 
were transfected individually to infected cells. We considered the following small GTPases: 
ARFs (1, 3, 4, 5 and 6), ARLs (1, 2, 3, 4A, 4C, 4D, 5A, 5B, 8A, 8B, 9, 10, 13B, 14, 15, 16 
and 17), ARF-related protein 1 (ARFRP1), Secretion-Associated Ras proteins 1A and B 
(Sar1A and Sar1B) and tripartite motif-containing protein 23 (Trim23). At 6 hours post-
infection the drug nucleozin was added to induce aggregate formation, and increase 
spatial co-localization of the proteins with vRNPs. Infection was stopped at 8 hours p.i. by 
cell fixation with PFA.  
 
 
Figure 3.1. Role of ARF and ARL proteins in the biogenesis of vRNP-carrying vesicles. Screen of 26 GFP-tagged 
proteins of the ARF family: ARFs (1, 3, 4, 5 and 6), ARFRP1, ARLs (1, 2, 3, 4A, 4C, 4D, 5A, 5B, 8A, 8B, 9, 10, 13B, 14, 15, 
16 and 17), Sar1 (A and B) and TRIM23 individually transfected in PR8-infected cells treated with nucleozin. At 8 hours p. i. 
cells were fixed and stained for viral protein NP. a) Individual overlapping areas between NP and each protein were sum and 
plotted as one dot per cell for comparison to the positive control Rab11-GFP (in pixel units). Co-localization between GFP 
and NP staining was assessed with ImageJ co-localization plugin. Red line in each column is the mean value of scores per 
candidate protein. The gray dotted line indicates the 20 pixel threshold. b) Representative images of cells transfected with 
ARL15-GFP (left panel), Rab11-GFP (middle panel) and GFP (right panel), infected with PR8 and treated with nucleozin 
from 6-8 h p.i.. At this time, cells were fixed and stained for NP protein (in red, middle panel) and imaged using the confocal 
microscope Leica Sp5. Scale bars represent 10µm. 
To quantify the co-localization of each ARF protein with vRNPs, we scored the area 
of pixels overlapping between GFP and NP staining in absence and presence of 
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nucleozin. Without nucleozin, no candidate protein was observed to co-localize with 
vRNPs (data not shown). In the presence of nucleozin, the sum of the overlapping areas 
per cell was plotted as individual dots in figure 3.1a. As expected, the area of 
colocalization of viral protein NP and Rab11 was the highest score (mean of 45.69 pixels), 
and hence was used as positive control.  Most ARFs tested gave modest values of co-
localization, comparable to those obtained for the negative control GFP and NP (mean of 0 
px). However, ARF5, ARFRP1, ARL13b ARL14b and ARL15 produced values higher than 
the 20 pixel threshold (means of 22.38, 21.75, 24.38, 22.06 and 45.65 pixels, 
respectively), being therefore good candidates to study further, as regulators of vRNP 
traffic.  The most promising among the candidates was ARL15, with the highest score that 
resembled that of Rab11. For this reason, the role of ARL15 in IAV infection was further 
characterized. 
3.1.2. Validation of the Screen 
3.1.2.1 Effects of depleting endogenous ARL15 in IAV production using A549 cells  
To validate the immunofluorescence-based screen, we made use of specific 
siRNAs for ARL15 (siARL15), or a control non-targeting RNA (siNT), to evaluate the effect 
of ARL15 depletion in viral production. For this purpose, three sequences that targeted 
endogenous ARL15 in the 3’ untranslated region (3’UTR) were assessed in their ability to 
efficiently deplete ARL15.  Thus, lung alveolar A549 cells were transfected individually with 
siRNAs targeting endogenous ARL15 (siARL15-1, -2 or -3), or with a combination of the 
three siRNAs in a mix, and with the control siNT for 36h (figure 3.2a). Afterwards, cells 
were infected at a MOI of 5 and at 16h p.i. supernatants were collected to quantify viral 
titers by plaque assays and cells were harvested for western blotting.  
siARL15 depletion efficiency was confirmed by western blot. As observed in figure 
3.2b, all siARL15 conditions efficiently reduced the levels of ARL15 in relation to the 
loading control GAPDH, in comparison to siNT. The levels of NP were used as a rough 
measure of the progression of infection in depleted vs non-depleted cells. As expected, 
uninfected cells did not express NP, whereas all conditions examined showed similar 
levels of NP in infected cells. This suggests that ARL15 does not influence early steps of 
the viral lifecycle, namely the entry stage and expression of viral proteins although further 
experiments should be performed to validate this assumption. The quantification of viral 
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titers (figure 3.2c) demonstrates that the knockdown of ARL15 led to a statistically 
significant reduction of viral production in all conditions. The most pronounced effect 
observed was obtained with siRNA-3 (15% ±7.5), although not statistically different to 
those of siARL15-1,2,3 (33% ±4.5) , siARL15-1 or -2 treatments (34% ±7.5, 35% ±1.0, 
respectively). From this point onwards, a mix of siARL15-1,2,3 was used whenever 
knockdown of endogenous ARL15 was required.  
Hence, this assay successfully demonstrated that depletion of endogenous ARL15 
affected viral production, reinforcing the outcome of the preliminary screen.    
 
Figure 3.2. ARL15 depletion in A549 cell line. A)  Strategy for ARL15 depletion. The following conditions were tested to 
deplete endogenous ARL15: non-targeting siRNA (siNT) as control; three individual siRNA targeting ARL15 3’UTR and a mix 
constituted of three siARL15 targeting 3’UTR of ARL15. (siARL15-1, -2, and -3). Upon depletion, cells were infected with 
PR8 at a MOI of 5, being harvested at 16 h p.i.:  b) ARL15, the viral protein NP and the loading control GAPDH were 
analyzed by western blotting, and c) supernatants were collected and virus titers measured by plaque assays. The mean of 
virus titers from two experiments were normalized to siNT control and plotted as percentage of plaque forming units per 
milliliter. One Way ANOVA test was performed, with 95% confidence. (***) P<0.001. 
 
 
3.1.2.2. Effects of depleting and rescuing ARL15 in IAV production using the 
ARL15-GFP stable cell line  
The lack of specificity in siRNA treatments, on account of off-target activity, has 
been well documented134,135. Therefore, rescue experiments were planned to confirm the 
requirement of ARL15 in infection, in which, upon gene silencing, cells would be 
transfected with the coding region of the targeted DNA to revert the observed effect.  
For this purpose, A549 stable cell lines were created expressing the GFP-tagged 
ARL15 used in the original screen. The presence of an endogenous sequence and a 
tagged construct coding for ARL15 enabled targeting independently these proteins by 
using siRNAs specific for different regions in the transcripts. Since ARL15-GFP plasmid 
lacks a 3’UTR, siRNAs targeting endogenous ARL15 3’ UTR would not affect ARL15-GFP. 
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In turn, ARL15-GFP would be depleted by siRNAs targeting the fluorescent tag. As a 
control, A549 stable cell lines expressing ‘GFP’ were included in assays. The cells were 
established by S Costa and A Seixas prior to the beginning of this master thesis. GFP and 
ARL15-GFP stable cell lines were passaged presenting similar growth rates and expected 
intracellular localization of the GFP protein expressed (Fig 3.3a and b). Furthermore, cells 
were equally permissive to infection, producing similar viral titers (figure 3.3c). Given the 
similarities presented by the two cell lines, and to limit the sampling size of each 
experiment, only the ARL15-GFP stable cell line was used for the subsequent assays. 
 
Figure 3.3. Characterization of A549 stable cell lines expressing GFP and ARL15-GFP. Cell lines were established 
using LentiORF pLEX-MCS Vector system (Thermo Scientific) according to manufacturer’s instructions.  Stable cell lines 
expressing GFP and ARL15-GFP were characterized for a) growth rates independently of viral infection, b) intracellular 
distribution of proteins (scale bars of 10µm) and c) viral production at 6, 8, and 16h p.i. upon PR8 infection at a MOI of 1.  
 
To perform rescue experiments, I have used the ARL15-GFP stable cell line to 
deplete: 1) GFP, or 2) endogenous ARL15, or 3) the two proteins combined (figure 3.4a). 
For this purpose, cells were transfected with different combinations of siRNAs: either with 
a GFP-targeting sequence (siGFP), siARL15, a mix containing siGFP and siARL15, and 
siNT as control, and were incubated for 36h. After this time, cells were infected at a MOI of 
5 for 16h, time at which supernatants and cells were harvested to perform plaque assays 
and western blots, respectively.  
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As above, depletion efficiency was confirmed by western blotting performed on 
cell lysates (figure 3.4b). Reduction in the levels of endogenous and overexpressed 
ARL15 was observed upon silencing (siARL15 and/or siGFP) when compared to the siNT 
control. Regardless of infection siGFP depleted ARL15-GFP but not ARL15 (figure 3.4b, 
lanes 3 and 4). Conversely, siARL15 only targeted ARL15 and not ARL15-GFP (lanes 5 
and 6). siGFP and siARL15 efficiently blocked production of both ARL15 forms (lanes 7 
and 8). Infection rate, as measured by NP staining, was invariable in all the conditions 
tested, when compared to the control. As in section 3.1.2.1, virus titers, normalized to 
control siNT, were reduced 10-fold (11%±2 PFU/mL) when siARL15 was transfected 
(figure 3.4c). Surprisingly, simultaneous silencing of endogenous and overexpressed 
ARL15 did not produce an exacerbation in the phenotype, as predicted. Rather, the levels 
of released virions were similar to those of siARL15 alone (15%±6 PFU/mL). However, 
targeting ARL15-GFP individually, resulted in an increase in viral titers (156% ±43), 
suggesting a role for ARL15-GFP in IAV inconsistent with the endogenous form.  
 
Figure 3.4. ARL15 depletion in A549 stable cell lines. a)  Strategy of depletion: a non-targeting siRNA (siNT) was used as 
control; GFP-targeting siGFP was transfected for ARL15-GFP depletion and siARL15 was used for the knock down of 
endogenous ARL15. The latter two siRNAs were combined to deplete the overexpressed and the endogenous forms of 
ARL15.  Cells were infected after 36 h of incubation, with an MOI of 5. At 16h p.i. b) cells were harvested for western blot. 
Approximately 10 000 cells ran in a 12.5% acrylamide gel, transferred to a nitrocellulose membrane and stained against GFP 
(ARL15-GFP), NP,  Glyceraldehyde 3-phosphate dehydrogenase protein (GAPDH) and endogenous ARL15.c) 
supernantants were collected and virus titers normalized to siNT control. One Way ANOVA test was performed, with 
confidence of 95%. (*) P<0.05; (**) P<0.01.Graphs include values obtained in two independent experiments. 
 
This assay suggested that either ARL15-GFP was not catalytically functional, or 
that siRNAs targeting the endogenous form of the protein were having off target effects, 
affecting other transcripts that influenced IAV infection.  
3.1.2.3. Rescue of viral production with ARL15-myc and ARL15-GFP constructs 
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To distinguish between the two hypotheses: non-functional ARL15-GFP or off-
target effects of the siARL15, complementary rescue experiments were performed using a 
new ARL15 plasmid cloned with a different tag. For this purpose, the coding sequence of 
ARL15 was fused to a tag containing 10 aminoacids (myc tag) instead of the 238 
aminoacids that constitute the GFP tag.   
Rescue experiments were performed to test, in parallel, the ability of ARL15-GFP 
and ARL15-myc to revert the effects of siARL15 on viral production. Notably, neither 
construct is susceptible to siARL15 as they lack the 3’UTR. For consistency, each sample 
was transfected with a siRNA and a plasmid as detailed in figure 3.5a. As controls, we 
transfected HEK 293T cells with the pGFP plasmid and the siNT siRNA. This condition 
was then compared to the following transfections: siARL15 with pGFP; siARL15 with 
pARL15-myc and siARL15 with pARL15-GFP. Of note, HEK 293T cells were used to 
ensure high transfection rates. Upon co-transfection with siRNAs and plasmids for 36 
hours, cells were infected with PR8 at a MOI of 5. Supernatants were harvested at 16 
hours p.i. for plaque assays and cells for western blotting to assess viral titers and viral 
protein expression, respectively.  
 
Figure 3.5. Rescue assay in HEK 293T cells. a) Strategy of transfection for the rescue assays. The following conditions 
were used: a control condition with non-targeting siRNA (siNT) and overexpression of pGFP; siARL15 and pGFP; siARL15 
and pARL15-myc, and siARL15 and pARL15-GFP. After 36 h incubation, cells were infected and mock infected and 
incubated for further 16h before assessing b) Viral and host cell expression by western blot of approximately 10 000 cells 
that were stained for NP, GFP, Myc, and GAPDH. c) Virus titers were normalized as percentage of the condition siNT & 
pGFP control. One Way ANOVA test was performed, with confidence of 95%. (*) P<0.05; (n.s.) non-significant. Experiments 
are representative of two independent repeats. 
Immunoblotting of cell lysates (figure 3.5b) confirmed that cells expressed the 
indicated transfected constructs and that NP levels, a measure of infection rate, were fairly 
constant in all the conditions, in comparison to the loading control GAPDH. 
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Figure 3.5c shows viral titers of all conditions as a percentage of the control siNT & 
pGFP. Consistent with previous assays, the depletion of ARL15 showed significantly 
decreased viral titers with pGFP overexpression (40% ±6). When depleted cells were 
supplemented with ARL15-GFP, viral titers remained similar to the previous condition, 
which is consistent with results of section 3.1.1, shown in figure 3.4c. However, pARL15-
myc transfection successfully rescued viral production to control levels (94% ±14 
PFU/mL), which confirms the role of ARL15 in IAV infection.  
This assay strongly suggested that the tag added to the C-terminus of ARL15 
somehow influenced its functionality. While the original screen assay, performed with the 
non-functional ARL15-GFP, resulted in co-localization of vRNPs and ARL15 in nucleozin-
induced aggregates, it is unclear whether this result would be observed with the ARL15-
myc plasmid. Therefore, in the following section, the presence of ARL15-myc in nucleozin-
induced vRNP aggregates will be assessed. 
 
3.1.3. ARL15-myc localization in infected cells treated with nucleozin 
With the intent of recapitulating the screen presented as preliminary data, the 
presence of ARL15 was analyzed by immunofluorescence in vRNP aggregates induced by 
nucleozin treatment. Several attempts were required to perform this simple experiment. At 
first, we tried to use commercially available antibodies against the endogenous ARL15, but 
the protein was not detected by immunofluorescence. To overcome this, the functional 
ARL15-myc was supplied exogenously to cells that were subsequently co-infected as in 
the original screen. However, the anti-myc antibody used in immunofluorescence did not 
detect any specific staining of ARL15-myc, suggesting that the tag was hidden once fused 
to ARL15. Finally, and upon several rounds of troubleshooting assays (data not shown), it 
was found that the antibody against ARL15 efficiently stained ARL15-myc. Thus, HeLa 
cells were transfected with the plasmid pARL15-myc for 16 hours and infected with PR8 at 
a MOI of 10. Nucleozin was added to a set of duplicate samples two hours prior to fixation, 
which took place at 8 and 10 hours p.i.. Cells were then immunostained against NP and 
ARL15 and imaged by confocal microscopy.  
In all infected conditions, ARL15-myc distribution consisted of cytoplasmic 
dispersed puncta, which lacked NP co-staining in cells without nucleozin (figure 3.6, 8h p.i. 
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and 10 h p.i. top lanes). As expected, in nucleozin-treated cells, NP distribution was 
altered from dispersed puncta, characteristic of vesicular transport, to large aggregates 
(figure 3.6, +Nz bottom lanes). These vRNP aggregates were however, devoid of ARL15 
and therefore, the two proteins did not overlap. However, close examination of aggregates 
showed that ARL15 could be observed in their vicinity. The significance of this proximity, if 
any, is still unclear.  
 
Figure 3.6. ARL15-myc is excluded from nucleozin-induced vRNP aggregates. HeLa cells transfected with pARL15-myc 
and infected at a MOI of 10. 2 hours prior to fixation, cells were treated or mock-treated with 2µM nucleozin and at 8 and 10 
hours post-infection cells were fixed. Samples were stained for ARL15 and viral protein NP. Images were acquired by 
confocal microscopy. Scale bars of 10µm. 
Hence, this assay did not recapitulate the initial screen that positively identified 
ARL15-GFP in vRNP-Rab11 vesicles. The most obvious difference between assays is the 
tag used in ARL15 plasmids, which could be the cause underlying the different outcomes. 
This hypothesis is in agreement with ARL15-GFP failure to rescue viral production in the 
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siRNA experiment, in contrast to the ARL15-myc version. In fact, these results allow the 
speculation that ARL15-GFP folded into a non-functional arrangement, that is either 
catalytically inactive or in which the GFP tag might be concealing a domain in ARL15 that 
is important during traffic. Tempting as it may be, this hypothesis awaits confirmation.  
Overall, the decreased viral production caused by the lack of ARL15, and the 
consistent rescue of this phenotype upon ARL15-myc overexpression, indicates that 
ARL15 plays a role during IAV infection that remains uncharacterized and will be the focus 
of the next chapter.  
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3.2. Characterization of ARL15 function during IAV infection 
3.2.1. Introduction on ARL15  
ARL15 function is unknown, although its predicted amino acid sequence suggests 
that it is structurally linked to ARFs (and Ras-related GTP binding proteins), which play key 
roles in regulating trafficking. Literature is limited to associations of ARL15 polymorphisms 
with diabetes136,137 and other diseases such as rheumatoid arthritis138, identified by 
genome wide screens. Generally, ARL15 is a conserved protein116, ubiquitously expressed 
in chordates and absent in lower eukaryotes. Figure S1, in supplementary data, shows the 
homology tree of the alignment between ARL15 sequences from humans, apes, mice, 
chickens, frogs, among others, with overall 63% identity. The remaining characterization of 
ARL15 is based on the predicted amino acid sequence. Thus, ARL15 is expected to be 
intracellular139, although it has also been identified extracellularly140, namely in exosomes 
isolated from urine141,142 and secretions of ovarian143 or prostatic144,145 cells.  
On a structural level, ARL15 characterization is based on sequence alignment for 
identifying functional domains. These include a GTPase region and a P-loop domain with a 
conserved nucleotide phosphate-binding motif – both characteristics are shared among 
ARFs (figure S2 in supplementary data). The homology tree in figure S3 was based on 
sequences retrieved from Uniprot database and show the SAR1 isoforms, SAR1a and 
SAR1b, as the closest members to ARL15. Alignments of the three peptides are depicted 
in figure S4, where algorithms predicted GTP and Mg²⁺ binding domains and ‘switch’ 
regions in ARL15 by comparison with SAR1. Finally, attachment of ARL15 to membranes 
might involve palmitoylation at the N-terminus on well-conserved cysteines116, instead of 
the typical myristoylation modification observed in the remainder ARFs.  
Overall, ARL15 is vastly uncharacterized and potentially involved in important 
human diseases that have been linked to trafficking defects146. The addition of a pathogen 
to this list, such as IAV, suggests that its role in regulating the secretory pathway might be 
more prominent than anticipated and argues in favor of studying its function.  
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3.2.2. Quantification of total ARL15 during infection 
In order to observe if ARL15 expression was altered during infection with PR8, cell 
lysates were collected over a time course and processed for western blotting. For this 
purpose, A549 cells were infected at a MOI of 5 with PR8, harvested at 4, 8, 12, 14, 16 
and 18h p.i. and stained for NP, ARL15 and GAPDH, as a way to assess infection, ARL15 
expression and control for sample loading. As expected, NP levels increased during the 
course of infection. Conversely, ARL15 was unaltered during infection (figure 3.7), 
presenting similar levels to those found in mock-infected cells. Furthermore, the 
maintenance of ARL15 levels throughout infection seems to be a general characteristic of 
IAV  infection as similar results were obtained with infection of other viral strains such as 
X31 (H3N2) and MUd (H1N1), see figure S5 in supplementary data.  
 
 
Figure 3.7. ARL15 levels during 
infection determined by western 
blot. A549 cells were infected at a MOI 
of 5 with PR8, and harvested at 4, 8, 
12, 14, 16 and 18h p.i.. Cell lysates 
were run in a 15% acrylamide gel, 
transferred to a nitrocellulose 
membrane and stained for NP, ARL15 
and GAPDH.  
 
 
Upon assessing the total levels of ARL15, we studied its intracellular distribution. 
The subcellular localization of most ARL proteins remains uncharacterized. However, 
these are expected to cycle between the cytosol and specific membranous compartments, 
depending on their activation status. ARFs when switched-off bind GDP and are cytosolic, 
whilst the GTP-bound forms are switched-on and recruited to their target membrane147, 
attracting effectors to execute its function. Therefore, viral-induced alterations in ARL15 
might not be regulated at the level of expression but rather downstream at the level of 
activation. The latter may be related with changes in distribution and will be assessed in 
the following section.   
  
GAPDH 
ARL15 
NP 
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3.2.3. Distribution of ARL15-myc during infection in HeLa cells 
In order to observe ARL15 localization during infection, pARL15-myc was 
overexpressed in HeLa cells (due to the antibody limitations previously described). Upon 
transfection for 16 hours, cells were infected at a MOI of 10 and fixed at 2, 4, 6, 8 and 10h 
p.i.. Samples from the last time points were, in addition, incubated with nucleozin two 
hours prior to fixation. Cells were then immunostained against ARL15, NP and the Golgi 
Brefeldin-A resistant guanine nucleotide exchange Factor 1 (GBF1), present at the cis-
Golgi and analyzed by confocal microscopy (figure 3.8a). 
In mock infected cells, ARL15 showed perinuclear accumulation consistent with the 
cis-Golgi that was marked by the host protein GBF1. In addition, ARL15 was found 
diffused within the cytoplasm, with increased concentration at the extremities, highlighting 
cellular edges and projections. Upon infection, the distribution of ARL15 was altered in two 
different ways. First, the overlap between ARL15 and GBF1 staining was progressively 
lost (figure 3.8a, right-side zoomed panel). These differences were quantified using 
Pearson Correlation Coefficient that decreased significantly during infection (figure 3.8b). 
Second, the presence of ARL15 at the extremities of cells also diminished, and cellular 
projections were no longer evident. These results indicate that ARL15 might leave the cis-
Golgi and cellular extremities, as soon as infection begins, remaining at an unknown 
subcellular compartment.  
Given that ARL15-myc and the ARL15-GFP constructs showed different abilities to 
rescue ARL15 depletion, the cellular distribution of ARL15-GFP was also examined. Our 
rationale was to identify if the changes in distribution of ARL15 would be required for its 
function in infection. This experiment was performed using the ARL15-GFP stable cell line, 
whose construct was unable to rescue depletion of endogenous ARL15.  
  Throughout infection, ARL15-GFP did not show differences in localization when 
compared to mock infected cells (figure S6 in supplementary data). It exhibited a 
cytoplasmic punctate distribution, accumulating at the cellular extremities and in a 
perinuclear compartment (possibly the cis-Golgi), and surprisingly it also stained the 
nucleoli. Providing that this construct might not be functional, the relevance of this 
distribution is unclear.  
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Figure 3.8. ARL15-myc distribution during IAV infection. (continues in the next page) 
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Figure 3.8. ARL15-myc distribution during IAV infection. a) HeLa cells were transfected with pARL15-myc and infected 
at a MOI of 10. Cells were fixed with 4% PFA at 2h, 4h, 6h, 8h, 10 h p.i. and stained for ARL15 (in red), the viral protein NP 
(in green) and GBF1 (in grey). In nucleozin treated cells, 2µM of the drug was added two hours prior to fixation. Images 
acquired by confocal microscopy. Error bars are of 10µm, except when mentioned. b) Pearson correlation coefficient for co-
localization between ARL15 and GBF1. 20 cells analysed per condition. One Way A-Nova test was performed, with 
confidence of 95%. (***) P<0.001. Assay and measurments performed once.  
 
Thus, these results suggest that the myc-tagged ARL15 changed its localization 
upon infection, whilst the GFP form did not. This observation corroborates that these 
constructs are indeed distinct, but additionally suggests that ARL15 needs to undergo an 
unknown alteration to positively influence viral infection, by an unknown mechanism that 
we aim to understand. The close proximity between ARL15 and cytoplasmic vRNPs and 
our preliminary screen argue in favor of assessing the role of ARL15 in promoting vRNP 
transport.  
 
3.2.4. vRNP distribution upon ARL15 depletion in A549 and ARL15-GFP stable cell 
lines 
To understand whether ARL15 was involved in vRNP trafficking, the strategy was 
to visualize the effects of depleting ARL15 in vRNP transport, using the above 
characterized siRNAs in both A549 cells and the ARL15-GFP stable cell line, the latter 
used as a control. Since the change in ARL15 distribution occurred at early stages in 
infection, the protein could facilitate traffic of the viral genome to the nucleus upon viral 
entry. Alternatively, the close proximity of cytoplasmic vRNPs and ARL15 late in infection 
also suggest that ARL15 could play a role in late stages of infection, namely in the 
transport of vRNP or other viral proteins to the sites of viral assembly. Literature postulates 
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that upon vRNP loading onto Rab11-positive vesicles, vRNPs are found in punctate 
cytoplasmic structures70,131–133, whose size increases during infection, as a result of 
impairment in recycling efficiency [Costa SV et al 2015, unpublished]. A failure in this 
loading process leads to a dispersed distribution of NP throughout the cytoplasm. 
 To this end, A549 or ARL15-GFP cells were transfected (in independent 
experiments) with siNT or siARL15. Additionally, the stable cell line was also treated with 
siGFP alone or in combination with siARL15. Upon transfection for 36h, cells were infected 
with PR8 at a MOI of 5 and fixed at 16 h p.i.. Then, cells were processed for 
immunofluorescence and stained for NP to be analyzed by confocal microscopy to assess 
trafficking of vRNPs. Figure 3.9 illustrates the depletion assays performed in A549 cells, 
and figure 3.10 in the ARL15-GFP stable cell line. The distribution of NP was found in 
punctate structures throughout the cytoplasm in both siRNA treatments in the two cell 
lines. This suggested that vRNPs were present in Rab11-positive vesicles with distribution 
characteristic of the recycling pathway, regardless of ARL15. However, the areas of 
vesicles of vRNPs seemed to be larger upon depletion of ARL15 in both cell lines tested. 
To quantify the area of NP vesicles, we used two strategies. The first was to plot the mean 
of the areas obtained per cell and the second was to separate vesicles into three arbitrary 
categories according to size: small vesicles ranged from 0 to 0.2 µm², intermediate size 
vesicles from 0.2 to 0.4 µm² and large with areas over 0.4 µm².  
 
Figure 3.9. vRNP distribution upon ARL15 depletion in A549 cells. a) A549 cells transfected with either siNT or siARL15-
1,2,3 for 36 hours, and infected at a MOI of 5. Cells were fixed at 16h p.i. in 4% PFA and immunostained against NP and 
Hoechst. Images were acquired by confocal microscopy. Scale bars represent 10µm. b) Vesicle size in each cell was 
measured using Fiji ’Analyse Particles’ plugin. The mean value of all vesicles’ area in a cell was represented by one dot 
plotted on the graph. Red line represents the median value. Student t-test was performed with confidence of 95%. (***) 
P<0.001. 35 cells were analysed per condition. c) Percentages of values plotted in b), distributed by ranges. Assay and 
measurements were performed only once and require repetition. 
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In A549 cells, vesicles carrying vRNPs duplicated in area when ARL15 was 
depleted, with median size of 0.32 µm², compared to the control siNT of 0.16 µm² (figures 
3.9a and b). This result was corroborated by a 64% increase in vesicles of intermediate 
size upon siARL15 treatment, as observed in the frequency distribution plot (figure 3.9c). 
Furthermore, cells treated with siARL15, rarely showed NP at the cell periphery.  
 
Figure 3.10. vRNP distribution upon ARL15 depletion in the ARL15-GFP stable cell line. a) A549 cells stably expressing 
ARL15-GFP were transfected for 36h with either siNT, siGFP, siARL15, or the latter two combined, and then infected at a 
MOI of 5. Upon fixation at 16h p.i., cells were immunostained against NP.  Images were acquired by confocal microscopy. 
Scale bars represent 10µm. b) Vesicle area in each cell was measured using Fiji ’Analyse Particles’ plugin, and the average 
plotted in a graph. Red line represents the median value. One Way ANOVA test was performed, with confidence of 95%. (*) 
P<0.05; (***) P<0.001. 20 cells were analysed per condition. c) Percentages of values plotted in b), distributed by ranges. 
Assay and measurements were performed only once and require repetition. 
In the stable cell line, endogenous ARL15 depletion likewise resulted in increased 
vesicle size. Consistently, the median area of vesicles was of 0.40 µm² for siARL15 and 
0.44 µm² for siARL15-siGFP conditions, when compared to control siNT whose vesicles 
showed a medium size of 0.30 µm². Moreover, the depletion of ARL15-GFP did not affect 
vesicle size, with median area of 0.26 µm² (figure 3.10a and b), which is also obtained in 
the frequency distribution plot (figure 3.10c). Although intermediate values remain constant 
in all transfections, the percentage in larger vesicles increased in siARL15 and 
siARL15/siGFP conditions by 30 and 60%, respectively. In addition, vRNPs were less 
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visible at the cell periphery, an observation that was facilitated by the GFP fluorescent 
background.  
Overall, the knock down of endogenous ARL15 consistently resulted in enlarged 
vRNP-carrying vesicles. Such enlargement could reflect the underlying reason for the 
reduced viral titers observed upon ARL15 depletion, in section 3.1 of Results. ARL15 
knock down seems to accumulate vRNPs in the cytoplasm, suggesting an impairment of 
vRNP transport towards the cellular periphery prior to budding out of the cell. Hence, we 
set up a strategy to observe if ARL15 would recruit vRNPs to Rab11 vesicles. 
 
3.2.5. Recruitment of vRNPs to the mitochondria upon transfection of Mito-Rab11 
and ARL15 
The viral genome, in the form of vRNPs, is loaded onto Rab11-positive vesicles 
upon nuclear export and is transported using the microtubule network towards the plasma 
membrane. The enlargement of NP vesicles could be explained by two hypotheses: 1) 
ARL15 depletion could promote vRNP loading on Rab11 vesicles or 2) it could inhibit 
vRNP delivery to the plasma membrane. Our group has implemented a synthetic system 
for the study vRNP-Rab11 traffic, based on the targeting of Rab11 to a random organelle, 
the mitochondria. Data acquired by other lab members show that in the case of Rab11-WT 
being targeted to this arbitrary compartment, vRNPs follow in a reasonable percentage, 
also localizing to the mitochondria (figure S7, supplementary data). In principle, the effects 
of ARL15 in promoting Rab11-vRNP interaction or delivery of vRNPs to membranes could 
be indirectly assessed by quantifying vRNP-Rab11 mitochondrial overlap in the presence 
or absence of ARL15. To perform this quantification, two forms of Rab11 were included: 
the wild-type (WT) able to bind vRNPs when switched on, and a GDP-bound dominant 
negative (DN) mutant, unable to recruit vRNPs.  
To perform this assay, HeLa cells were co-transfected with two sets of plasmids: 1) 
pARL15-myc or pGFP as control and 2) a mitochondria-targeted plasmid expressing 
either: mcherry alone as a control (pMito-cherry) or fused to Rab11-WT or -DN forms 
(pMitoRab11aWT and pMitoRab11aDN). Upon infection with PR8 at a MOI of 20, cells 
were fixed at 16 hours p.i., immunostained against NP and ARL15 and imaged by confocal 
microscopy. Co-localization between mitochondria-targeted constructs and NP staining 
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was assessed using Fiji ‘Colocalization Finder’ plugin, the Pearson’s correlation coefficient 
was measured per cell and plotted in a graph.  
The vRNP localization at the mitochondria produced mean negative scores for 
control MitoCherry and MitoRab11-DN constructs, verifying that these are unable to recruit 
the viral genome, independently of the addition of ARL15 (figure 3.11a and b). In case of 
MitoRab11-WT overexpression, vRNPs localized to the mitochondria when the positive 
control GFP was co-transfected, whereas it appeared more diffuse in the presence of 
ARL15-myc. Scores support the observed effect caused by ARL15 in vRNP distribution, 
having mean values of 0.23 and 0.06 for pGFP and pARL15-myc, respectively. Although 
indirect, these results indicated that ARL15 might contribute to vRNP unloading of Rab11. 
This premise associated with the evidence of ARL15 being a positive regulator of IAV 
infection suggests that such a step would occur late in infection.  
Overall, the data herein presented supports a relevant role for ARL15 in facilitating 
vRNP traffic at late stages of IAV infection, with a role in disturbing the binding of vRNPs to 
Rab11.  
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Figure 3.11. ARL15 affects the recruitment of vRNPs by Rab11. (continues in the next page) 
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Figure 3.11. ARL15 affects the recruitment of vRNPs by Rab11. a) HeLa cells infected at a MOI of 20 and co-transfected 
with the following plasmid combinations: 1) Mitochondria targeted cherry (top panel), cherry-Rab11-WT (middle panel) or 
cherry-Rab11-DN (bottom panel) and 2) GFP or ARL15-myc. Cells were fixed in 4% PFA at 16h p.i. and stained for ARL15 
and viral protein NP. Images acquired by confocal microscopy. Error bars of 10µm. b) Pearson correlation coefficient for co-
localization between cherry-tagged construcs and NP. 20 cells were analysed per condition and One Way A-NOVA test was 
performed, with confidence of 95%. (***) P<0.001. Assay and measurments performed once.  
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CHAPTER 4 | Discussion 
 
IAV is an important human pathogen that provokes frequent epidemics worldwide. 
Its infection is currently prevented by: vaccines that require constant updating on account 
of continually mutating viruses and antivirals, targeting NA, susceptible to select resistant 
strains. Novel antiviral strategies are needed and an alternative strategy could target key 
host pathways in sustaining viral replication. Recent findings revealed that IAV uses the 
recycling endosome for trafficking of the newly-synthesized viral genome, i.e. vRNPs. The 
major regulator of this compartment, Rab11, is known to bind progeny vRNPs, upon 
nuclear export. All segments that constitute the viral genome are loaded onto Rab11-
positive vesicles and transported using the microtubule network towards the plasma 
membrane. It is likely that other host factors influence these processes, such as members 
of the ARF-family, since these, along with Rabs, control vesicular trafficking to ensure 
specific cargo delivery.  
To determine the involvement of ARF-family members in IAV infection, we 
screened for the presence of these proteins overlapping with vRNP-carrying vesicles in an 
immunofluorescence based assay. For this purpose, GFP-tagged proteins were 
overexpressed in infected cells treated with nucleozin, a drug that specifically aggregates 
vRNP-Rab11 vesicles. The experiment provided a strong candidate, ARL15, which co-
localized with NP aggregates in levels equivalent to those exhibited by Rab11. This ARL 
was never considered as a host factor required for IAV infection in genome wide 
screens148–151, being very infrequently mentioned in literature. Nevertheless, it was 
identified as a genetic risk factor in diseases with marked trafficking defects such as 
diabetes and rheumatoid arthritis136–138, and for all these reasons was the object of this 
thesis. 
Depletion of the endogenous ARL15 decreased viral titers by 60-90% in all cell 
lines tested, suggesting that ARL15 has a positive role in the IAV lifecycle (see figures 3.2 
and 3.4). However, the depletion of the exogenously supplied ARL15-GFP could not 
rescue viral production (figure 3.4), in the ARL15-GFP stable cell line. These conflicting 
results could be attributed to: 1) siRNA off-target effects on transcripts other than the 
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endogenous ARL15 or 2) impairment in ARL15 activity caused by the addition of the bulky 
GFP tag. To distinguish between the two scenarios, rescue assays were performed using 
a distinct plasmid encoding ARL15 fused to the myc-tag (figure 3.5). Remarkably, ARL15-
myc, unlike ARL15-GFP, was able to rescue viral titers to control levels, indicating that 
ARL15 favored IAV infection and validating the screen herein presented as preliminary 
data. However, results also suggested that the GFP-tagged construct was somehow non-
functional. The premise for the initial screen was to find functional ARF/ARLs in vRNP 
aggregates. Since ARL15-GFP was suggested to be non-functional, ARL15-myc 
distribution was assessed in enriched vesicular content of vRNPs and Rab11 induced by 
nucleozin, and found to be excluded from vRNP aggregates (figure 3.6). Close inspection 
of these aggregates showed that ARL15 was consistently found in their vicinity. 
Nevertheless, this result contrasts with the one obtained with the initial screen due to 
reasons that are unclear at this point. Still, the observed proximity between vRNP 
aggregates and ARL15, suggests that they might interact, although via an intermediate 
complex able to bridge ARL15 to an undefined component of vRNP-carrying vesicles. 
Such a mechanism resembles other cellular mechanisms described, for example, the 
ability of ARL8 to recruit the effector SKIP which attracts Kinesin-1 to control the 
distribution of lysosomes127.   
Hence, ARL15 emerges as an important host factor for IAV, with an unidentified 
role both in the context of IAV infection as well as in the cell in general. ARL15 expression 
did not change throughout the course of infection with three viral strains (figures 3.7 in 
Results and S5 in supplementary data). This result is in agreement with the broad 
understanding that ARFs are regulated at a downstream level through 
activation/inactivation cycles102,116. In agreement, ARL15 subcellular localization changed 
during infection as observed by immunofluorescence (figure 3.8). In uninfected cells, 
ARL15 accumulated mostly at the cis-Golgi, co-localizing with GBF1, and was also found 
in cellular projections. Upon infection, ARL15 re-localized from the cis-Golgi and cell edges 
to cytoplasmic distinctive puncta that have not yet been identified. The change in 
distribution occurred early in infection and was maintained until 10 hours post-infection, but 
failed to co-localize with vRNP vesicles. Moreover, GBF1 accumulation was consistently 
perinuclear throughout infection. GBF1 is an ARF-GEF protein that initiates the coating of 
nascent vesicles from the cis-Golgi in the early secretory pathway and has been implicated 
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in the replication of many RNA viruses152–155.  Slight changes observed in GBF1 pattern 
can be explained by Golgi morphological alterations known to occur during IAV 
infection156. Interestingly, the distribution of the non-functional ARL15-GFP expressed in 
the stable cell line did not change during infection, being present in the perinuclear area 
and in cell projections. These differences strongly support that ARL15 is relocated during 
IAV infection to the vicinity of aggregates to perform an undescribed function.  
Initially, we sought to understand the point at which ARL15 was involved in vRNP 
trafficking. The early exit of ARL15 from GBF1-positive locations observed in figure 3.8a 
and quantified in figure 3.8b, supported a role of ARL15 in the initial steps of infection, for 
instance, in the transport of vRNPs to the nucleus (hypothesis 1 in figure 4.1). 
Alternatively, the close proximity of ARL15 to vRNP aggregates, likewise justified its 
involvement at later stages of infection (hypothesis 2 in figure 4.1). Both theories 
presented in figure 4.1 are not mutually exclusive. In fact, CD81 was reported to affect viral 
uncoating in the early steps of viral infection as well as to impact the budding of IAV 
particles94.  
 
Figure 4.1. Predicted outcomes for depletion of ARL15. Hypothesis 1: ARL15 could affect the initial steps in viral 
infection such as receptor bindind, internalization, fusion to endosomes, nuclear import or, Hypothesis 2: ARL15 could 
affect steps in viral assembly, such as accumulation of vRNPs at the microtubule-organizing center, loading onto Rab11 
vesicles, trafficking of vesicles throughout the recycling endossome. Illustration by MJ Amorim, unpublished. 
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To discriminate between the two hypotheses, ARL15 was depleted from cells and 
the effects on vRNP trafficking were observed. Results indicate that ARL15 functions in 
late stages of infection, as removing it did not affect vRNP entry into the nucleus, NP 
expression (figure 3.2, siNT vs siARL15 lanes) or vRNP loading on Rab11 vesicles. The 
latter observation is substantiated by reports describing that vRNP loading onto Rab11-
positive vesicles, resulted in a punctate cytoplasmic distribution of NP, whose size 
increased during infection70,79,131–133 [Costa SV et al 2015, unpublished]. Depletion of 
Rab11 caused a failure in this loading process, resulting in a dispersed distribution of NP 
throughout the cytoplasm70. The absence of ARL15 not only resulted in the cytoplasmic 
accumulation of distinct puncta but also in their enlargement, suggesting that ARL15 plays 
a role in vRNP transport. At this stage we can only suppose that these enlarged vesicles 
contain Rab11, an assumption substantiated by the fact that appearance of puncta is 
dependent on Rab1179. 
The enlargement of vRNP-containing puncta upon ARL15 depletion is an 
interesting feature that we are yet to clarify. Enlargement of vesicular size presumes that 
Rab11 vesicles are transitory platforms for vRNP transport to the assembly sites. In 
agreement, this concept is supported by the following observations: 1) Rab11 is found in 
minimal amounts inside virions157,158, 2) Rab11 fails to co-localize with vRNPs at the 
plasma membrane30,132, and 3) vRNPs do not present a head-to-tail orientation inside a 
virion, implicating, at least a partial vRNP-Rab11 detachment, resulting in an up-side-down 
organization of segments159. The vesicular enlargement observed in the absence of 
ARL15 could result from disturbing the transitory staging at two levels: 1) by leading to an 
increased loading of vRNPs on Rab11 vesicles (Pre-loading hypothesis in figure 4.2); or 
2)a failure in a final yet uncharacterised step occurring subsequently to the staging area 
(Post-loading hypothesis in figure 4.2). We explored the involvement of ARL15 in vRNP 
recruitment by Rab11 via the artificial targeting of the Rab 11 to the mitochondria. Our 
premise was that if ARL15 were to be involved in loading of vRNPs onto Rab11 vesicles 
described in the ‘Pre-loading hypothesis’, overexpressing ARL15 would result in vRNP 
increase in the mitochondria, and the contrary would be observed if ARL15 promoted 
vRNP dissociation, or competed with Rab11 for vRNP binding. We observed that 
MitoRab11-WT binding to vRNPs was significantly reduced when ARL15 was present 
(figure 3.11). In this case, vRNPs distributed between the mitochondria and the cytoplasm. 
FCUP 
The role of ADP-ribosylation factor-like 15 in influenza A virus infection 
56 
 
 
Importantly, ARL15 did not localize at the mitochondria in the presence of either Rab11-
WT or DN, indicating that the protein does not bind directly to Rab11 and does not 
compete for vRNP binding. This is also corroborated by the lack of ARL15 in vRNP-Rab11 
aggregates during infection (figure 3.6). Altogether, it is possible that ARL15 influences the 
trafficking of Rab11-vRNP vesicles by contributing to the inactivation of Rab11 at later 
stages of infection, promoting the final delivery of vRNPs to the plasma membrane.  
 
 
Figure 4.2. Predicted outcomes for the role of ARL15 during vRNP trafficking. Pre-loading hypothesis: ARL15 avoids 
overloading of the RE with vRNPS by switching of Rab11, promoting affluent transport towards the plasma membrane. Post-
loading hypothesis: ARL15 may faccilitate the transfer of vRNPs to the assembly sites by unloading the vesicles and 
switching off Rab11. Illustration by MJ Amorim, unpublished. 
 
In agreement, experiments from our group suggest that vesicular increase is 
observed after overexpression of a constitutively active (CA) form of Rab11, and this 
increase is accompanied by a decrease in virion production. This observation supports the 
existence of an additional step that requires switching-off Rab11 for efficient vRNP delivery 
to the plasma membrane [Costa SV et al 2015, unpublished]. Furthermore, Eisfeld et al.,  
had already suggested that the vRNP-Rab11 interaction could be disrupted prior to virion 
budding, perhaps via vRNP recruitment by the viral proteins M1-M2 associated at the 
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plasma membrane132. Overall this work supports the model of vRNP-Rab11 disruption, as 
ARL15 depletion contributed to the formation of enlarged cytoplasmic vRNP-carrying 
vesicles and decreased viral titers. Finally, it is becoming accepted that the intermediate 
staging area works as a platform to promote the interactions between 8 different vRNPs 
that are necessary to form a viral particle74,81. In this case, ARL15 might contribute to 
infection at this stage. At the present we can only speculate on its role but favor two 
theories: 1) ARL15 might be involved in the delivery of vRNPs to the plasma membrane or 
2) might facilitate retrograde transport of Rab11 to the TGN to load more vRNPs. Be as it 
may, ARL15 was not found in virions and therefore must not be the final acceptor of 
vRNPs157. 
Our working hypotheses revolve around mechanisms affecting vRNP transport. 
However, it is equally possible that ARL15 affects other steps in viral infection that we fail 
to investigate during this thesis. Initial steps seem to operate normally; however, the 
quantification of viral transcription and replication rates as well as the evaluation of viral 
protein expression, beyond NP, are crucial to fully characterize the role of ARL15. 
Similarly, it might influence trafficking of the remaining virion components, including for 
example M1, M2, HA and NA. Quantification of the three transmembrane proteins at the 
cell surface by flow cytometry is necessary to discard this hypothesis, as the measurement 
of M1 levels, beneath the plasma membrane or inside virions, would provide evidence 
concerning ARL15 involvement in M1 trafficking.  
In conclusion, this thesis shows evidence that ARL15 is an important host protein 
that facilitates vRNP traffic at late stages of IAV infection. Its intracellular distribution is 
sensitive to infection and its absence results in deficient transport of vesicles carrying the 
vRNPs, leading to their accumulation in the cytoplasm. Furthermore, our data shows that 
ARL15 significantly disturbs the binding of vRNPs to Rab11, indicating that it may 
contribute to a yet uncharacterized Rab11 inactivation step before vRNPs reach the 
membrane. However, these constitute the initial steps of ARL15 characterization in the 
viral lifecycle. In the future, complementary studies should assess the consequences of 
targeting this pathway for antiviral therapy.  
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CHAPTER 5 | Future perspectives  
 The data herein presented revealed that ARL15 positively influences IAV infection 
presumably by disturbing the interaction between the viral genome and small GTPase 
Rab11 and aiding in vRNP transfer to the plasma membrane for budding. However, 
ARL15 characterization remains incomplete either in context of infected or uninfected 
cells. To complete this study with the following analysis would be required.   
Firstly, not much is known about the role of ARL15 in the normal cell. Biochemical, 
imaging and genetic assays should be used to evaluate the intracellular localization, 
catalytic activity and regulation mechanisms of ARL15, determining important domains for 
the predicted function of the protein and putative associations with cellular membranes.  
Secondly, the role of ARL15 during IAV infection lacks characterization. The study 
herein presented does not elucidate in detail the relation between ARL15 and Rab11. One 
way to explore such interaction could be to perform pull down assays evaluating the 
outcomes of vRNP-Rab11 ligation in the presence of ARL15, by using the already 
established HEK 293T cell lines expressing WT, CA and DN forms of Rab11. Likewise, it 
would be of interest to analyze biochemically whether ARL15 binds the Rab small GTPase 
or any of its identified interacting proteins. Alternatively, one could analyze the effects on 
viral production after supplementing Rab11-WT and ARL15, for which a dominant negative 
form of Rab11 could be used as control.  
Thirdly, the lack of co-localization of ARL15 with GBF1 should be further 
investigated, namely the identification of ARL15 compartment in infection and molecular 
mechanisms underlying this change.  
Fourthly, the effects of ARL15 depletion on other viral steps should be analyzed, 
mostly due to the importance of ARLs in regulating trafficking pathways. In this sense, the 
intracellular transport of other proteins such as HA, NA and M2 should be assessed by 
flow cytometry, as these proteins reach the plasma membrane via the classical secretory 
pathway. In parallel, the distribution of M1 and its role in the particle assembly should also 
be evaluated in the presence or absence of ARL15. The involvement of viral M1 in the 
later stages of infection is poorly understood. It is supposed that M1 binds the cytoplasmic 
tail of M2 and aids vRNP packaging at the plasma membrane34. Thus, the interaction 
between M1 and M2 in the absence of ARL15 would constitute an important assay 
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elucidating this particular step. In addition to the trafficking of viral components, particle 
budding and the ultrastructure of virions should also be evaluated as a measure of 
efficiency in the very last step of infection, which could be easily accomplished by electron 
microscopy. 
Finally, the studies proposed so far include tissue cultured cells resorting to siRNA 
treatments to deplete ARL15 that are useful but not devoid of limitations. In order to study 
infection in vivo in cells without ARL15 we have started the process of establishing ARL15 
knock-out mice, using the CRISPR-Cas9 system. This procedure was initiated during the 
course of my internship. My contribution was to clone an ARL15 sequence fused to a 
guide RNA, with the purpose of coding the RNA segment responsible for guiding the 
nuclease to the target ARL15 gene. Mouse embryonic fibroblast cells, permissive to IAV 
infection, will be isolated from these mice and used to corroborate all the observations 
achieved so far as well as used to validate biochemical assays previously performed. 
Additionally, these knock out mice are invaluable to characterize the effect of ARL15 on 
viral pathogenesis, immune response and inflammation.  
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CHAPTER 7 | Supplementary Data 
 
 
Figure S1. Homology tree of ARL15 of chordate species.  Sequences retrieved from Uniprot© database, alligned using 
Clustal Omega to produce the homology tree output. Stars highlight sequences that were manually annotated. The 
remaining sequences were processed by TREMBL. The overall aminoacid sequence identity is of 63%. The aminoacid 
sequence identity of starred sequences is of 93%. Uniprot references of ARL15 sequences: Ss: C0HAE3; Gg:F1NMW9; Xl: 
Q6DJE1; Bt: Q5EA19; Mmusculus: Q8BGR6; Cj: U3EFB9; Pa: Q5RFN0; Mmulata: H9ESN0; Hs: Q9NXU5; Pt: K7AXD4. 
 
 
 
 
Figure S2. ARL15 anotation. Sense and antisense coding sequences, and correspondant translation of ARL15 protein 
(NP_061960.1). Information retrieved from the National Center for Biotechnology Information (NCBI©) database. Prediction 
of major domains, common to SAR1 protein.   
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Figure S3. Homology tree with members of the human ARF-family. Identity: 0.3%. Sequences retrieved from Uniprot© 
database, allignment performed using Clustal Omega. All sequences have a reviewed status. The relative positions of 
ARL15, SAR1a and SAR1b are highlighted with a blue bar. Uniprot references of human: ARF1 (P84077); ARF3 (P61204); 
ARF4 (P18085); ARF5 (P84085); ARF6 (P62330); ARFRP (Q13795); ARL1 (P40616); ARL10 (Q8N8L6); ARL11 (Q969Q4); 
AR13A (Q5H913); AR13B (Q3SXY8); ARL14 (Q8N4G2); ARL15 (Q9NXU5); ARL16 (Q0P5N6); ARL17 (Q8IVW1); ARL2 
(P36404); ARL3 (P36405); ARL4A (P40617); ARL4C (P56559); ARL4D (P49703); ARL5A (Q9Y689); ARL5B (Q96KC2); 
ARL5C (A6NH57); ARL6 (Q9H0F7); ARL8A (Q96BM9); ARL8B (Q9NVJ2); ARL9 (Q6T311); TRI23 (P36406); SAR1A 
(Q9NR31); SAR1B (Q9Y6B6). 
 
Figure S4. Alignment of human ARL15, SAR1a and SAR1b proteins. Sequences retrieved from Uniprot© database, 
alignment performed using Clustal Omega, with overall identity of 19%. Highlight of ARL15 predicted minor domains, 
associated with general catalytic functions of small GTPases; annotation retrieved from the NCBI© database. Sequence 
references: Q9NXU5, Q9NR31, Q9Y6B6. 
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Figure S5. ARL15 levels during infection determined by western blot. A549 cells were infected at a MOI of 5 with IAV 
strains X31 and Mud, and harvested at 4, 8, 12, 14, 16 and 18h p.i.. Cell lysates were ran in a 15% acrylamide gel, 
transferred to a nitrocellulose membrane and stained for NP, ARL15 and GAPDH.  
 
 
 
Figure S6. ARL15-GFP distribution during IAV infection. a) A549 ARL15-GFP stable cell lines were infected (MOI of 5). 
Cells were fixed in 4% PFA at 2h, 4h, 6h and 8h post-infection and stained against Rab11 and viral protein NP. Images 
acquired by confocal microscopy. Error bars of 10µm. 
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Figure S7. Mitochondria-targeted and cherry-tagged constructs. HeLa cells transfected with (top panel) pMitoRab11-WT 
(middle panel) pMitoRab11-DN and (bottom panel) pMito-cherry and infected (MOI of 20). Cells were fixed in 4% PFA 16h 
p.i. and stained against mitochondria protein HSP60 and viral protein NP. Images acquired by confocal microscopy. Error 
bars of 10µm.  
 
 
  

